Telomerase reverse transcriptase treatments for renal fibrosis and non-human animals thereof

By developing a mouse model with AAV9 vehicle containing TERT coding sequence and sublethal dose folic acid treatment, the technical difficulties of studying short telomeres in renal fibrosis were solved, and effective simulation and potential treatment options for renal fibrosis were achieved.

CN118946266APending Publication Date: 2024-11-12FUNDACION CENTRO NATIONAL DE INVESTIGACIONES ONCOLGICAS CARLOS III
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202280094088.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-01-24
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art lacks effective mouse models to study the role of short telomeres in renal fibrosis, and it is not clear whether telomerase-deficient mice will spontaneously develop renal fibrosis or whether additional stimulation is required to cause disease.

Method used

nucleic acid vectors containing telomerase reverse transcriptase (TERT) coding sequences were developed for the treatment of renal fibrosis associated with short telomeres, using non-integrated vectors based on adeno-associated viruses, especially derived from serotype 9 A vector of adeno-associated virus (AAV9) combined with sublethal doses of folic acid-treated mouse models to study and treat renal fibrosis.

Benefits of technology

A mouse model for studying short telomeres in renal fibrosis was successfully established, demonstrating the characteristics of renal dysfunction and fibrosis in telomerase-deficient mice after sublethal dose of folic acid treatment, providing a potential method for gene therapy. Extend the length of telomeres and slow down the progression of renal fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005056526750000171
    Figure BDA0005056526750000171
  • Figure BDA0005056526750000181
    Figure BDA0005056526750000181
  • Figure BDA0005056526750000191
    Figure BDA0005056526750000191
Patent Text Reader

Abstract

The present invention provides compositions and methods for treating and preventing conditions associated with short telomere length, in particular renal fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the fields of molecular biology, biotechnology and medicine. More specifically, the present invention relates to non-human animals and compositions and methods for treating conditions associated with short telomere length. More specifically, the present invention relates to compositions and methods for treating conditions associated with renal fibrosis associated with short telomere length. Background Art

[0002] Telomeres are special structures at the ends of chromosomes that protect the ends of chromosomes from DNA repair and degradation activities. Mammalian telomeres are composed of TTAGGG repeat sequences and are bound to a multiprotein complex called shelterin. The minimum length of the TTAGGG repeat sequence and the integrity of the shelterin complex are crucial for telomere protection, as shortened telomeres are associated with many diseases. These structures are essential for chromosome integrity by preventing telomere fusion and telomere fragility. Telomere length is controlled by the ribonucleoproteinase telomerase, which can add telomere sequences to telomeres de novo. Telomerase is a cellular reverse transcriptase (TERT, telomerase reverse transcriptase; also known as TP2; TRT; EST2; TCS1; hEST2) that can compensate for telomere loss by adding TTAGGG repeat sequences de novo at the ends of chromosomes using the associated RA component as a template (Terc, telomerase RNA component). Telomerase is expressed in most adult stem cell compartments; however, this is not sufficient to maintain telomere length, as evidenced by the shortening of telomeres in most human and mouse tissues with age.

[0003] Because telomere sequences are naturally lost with each cell division (known as the end replication problem), and because somatic cells express telomerase at very low levels or not at all, telomeres shorten throughout life. When telomeres become critically short, they lose their protective function and trigger a persistent DNA damage response at the telomeres, leading to a cellular senescence response (Harley et al., 1990, Flores et al., 2008).

[0004] Accumulation of short telomeres is a hallmark of aging. Mutations in telomerase or telomere-binding proteins lead to telomere shortening or dysfunction and result in a human pathology known as “telomere syndrome,” characterized by loss of tissue regenerative capacity and fibrotic pathology, including some examples of aplastic anemia, dyskeratosis congenita, and pulmonary fibrosis. Adeno-associated virus (AAV)-based telomerase gene therapy was found to be beneficial for extending healthy lifespan in the context of normal physiological aging in wild-type mice. Adult and aged mice were treated with AAV9-mTERT gene therapy to ubiquitously express the mouse telomerase catalytic subunit (mTERT). A range of physiological parameters (glucose and insulin tolerance, osteoporosis, neuromuscular coordination, rotarod, etc.) showed that mice treated with TERT had a significantly increased healthy lifespan and a slower aging rate. In addition, the average lifespan of adult and aged mice increased by 24% and 13%, respectively, compared with controls. A single intravenous administration of AAV9-TERT to adult mice resulted in increased telomere length in peripheral blood cells (Bernardes de Jesus et al., 2012). These results highlight the importance of mouse models for studying specific pathologies and potential therapeutic approaches.

[0005] Chronic kidney disease (CKD) is a high-mortality condition with an increasing incidence due to an aging population. Renal fibrosis is a major determinant of end-stage renal disease and is characterized by fibroblast activation and overproduction and deposition of extracellular matrix (ECM), leading to renal parenchymal destruction, inflammatory and fibrotic responses, and decreased renal function. It is thought that short telomeres may contribute to renal fibrosis. However, the role of short telomeres in renal fibrosis remains poorly understood, in part due to the lack of suitable mouse models. Furthermore, it is unclear whether telomerase-deficient mice with short telomeres develop renal fibrosis or whether they require additional stimuli to develop the disease. In the past, we have developed mouse models of aplastic anemia as well as pulmonary fibrosis associated with short telomeres. These mouse models demonstrate the role of short telomeres in the origin of these diseases and point to potential therapeutic strategies.

[0006] In the present invention, we developed a suitable mouse model to study renal fibrosis associated with short telomeres, which enabled us to investigate whether telomerase activation could be an effective treatment to alleviate renal fibrosis associated with short telomeres.

[0007] The present invention provides compositions and methods for treating and preventing renal fibrosis associated with short telomeres. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] Figure 1 : Mouse model of renal fibrosis is associated with short telomeres. a. Schematic diagram of experimental method. On day 0, 8-9 weeks old Tert + / + or G3 Tert- / - Mice were administered increasing doses of FA (0, 50, 100, and 125 mg kg -1 Body weight (BW)). Blood samples were collected for analysis one and two weeks after FA administration. Mice were euthanized on day 14. b.Tert + / + , Tert treated by FA + / + 、G3Tert - / - and FA-treated G3 Tert - / - Macroscopic appearance of kidneys at the end point of mice. c, d. Untreated and FA-treated Tert + / + Mouse and G3 Tert - / - Serum creatinine (c) and BUN (d) levels in mice. e. Tert at the end point + / + , Tert treated by FA + / + 、G3Tert - / - and FA-treated G3 Tert - / - Representative images and quantification of Masson and PAS+D staining in mice. Statistical analysis was performed using two-way analysis of variance (ANOVA) and post hoc Bonferroni test. Data are presented as mean ± sem. The number of mice analyzed for each genotype is indicated (n). *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. NS: not significant.

[0009] Figure 2 :Telomerase-deficient mice treated with sublethal doses of folic acid developed severe renal dysfunction. a. Schematic diagram of the experimental method. + / + and G3 Tert - / - Mice were given 125 mg kg -1 FA dose per body weight. b. Urine albumin to creatinine ratio (UACR). c. Untreated and FA treated Tert + / + and G3 Tert - / - Macroscopic appearance of mouse kidneys. d. Untreated and FA-treated Tert + / + Kidney and G3 Tert - / - Representative images and quantification of Masson's trichrome, Sirius red, and PAS+D staining in kidney. Statistical analysis was performed using one-way ANOVA with post hoc Tukey test and two-way ANOVA with post hoc Bonferroni test. Data are presented as mean ± sem. The number of mice analyzed for each genotype is indicated. **P ≤ 0.01 and ***P ≤ 0.001.

[0010] Figure 3 :Telomerase-deficient mice develop collagen deposition and activated myofibroblasts in the kidneys after sublethal administration of folic acid. a.Tert+ / + , Tert treated by FA + / + 、G3 Tert - / - and FA-treated G3 Tert - / - Representative images and quantification of α-SMA, fibronectin, collagen type VI, and double immunofluorescence of α-SMA and vimentin in mice. b.Tert + / + , Tert treated by FA + / + 、G3 Tert - / - and FA-treated G3 Tert - / - Double immunofluorescence of α-SMA and Ki67 in mice. White arrows indicate α-SMA + Ki67 + c. On day 14 after FA administration, Tert + / + , Tert treated by FA + / + 、G3Tert - / - and FA-treated G3 Tert - / - Relative mRNA expression of Acta2, Vim, Col1a1, Col3a1, Col4a1, and Fn1 in mice. Statistical analysis was performed using one-way ANOVA and post hoc Tukey test. Data are presented as mean ± sem. The number of mice analyzed for each genotype is indicated. **P ≤ 0.01 and ***P ≤ 0.001. Vh: vehicle.

[0011] Figure 4 : Sublethal folic acid administration increases renal apoptosis and senescence in telomerase-deficient mice. a–d.Tert + / + , Tert treated by FA + / + 、G3 Tert - / - and FA-treated G3 Tert - / - Representative images and quantification of immunohistochemical staining of CC3 (a), p21 (b), p53 (c), and γ-H2AX (d) in mice. Inset: magnified image. e.Tert + / + , Tert treated by FA + / + 、G3 Tert - / - G3Tert with FA treatment - / - Representative images of Q-FISH analysis of mice and quantification of mean total nuclear telomere length. Magnified images are shown below. auf: arbitrary fluorescence units. Statistical significance was determined by one-way ANOVA and post hoc Tukey test. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. Data are presented as mean ± sem. The number of mice analyzed for each genotype is indicated.

[0012] Figure 5 : Short telomeres induce renal tubular damage and immune infiltration. a. After 14 days of low-dose FA administration, Tert + / + , Tert treated by FA + / + 、G3 Tert - / - and FA-treated G3 Tert - / - Relative expression of Havcr1, Lcn2, and Emr1 in mice. b. Representative images and quantification of immunohistochemical staining for F4 / 80, CD3e, CD4, and CD8a. Insets: magnified images. Statistical analysis was performed using one-way ANOVA and post hoc Tukey test. Data are presented as mean ± sem. The number of mice analyzed for each genotype is indicated. **P ≤ 0.01 and ***P ≤ 0.001.

[0013] Figure 6 :EMT and TGFβ signaling pathways are overactive in telomerase-deficient mice. a, b. -1 Body weight of 10-week-old Tert treated with FA + / + and G3 Tert - / - Gene expression data obtained by RNA-seq of mouse kidney samples. Mice were euthanized on day 14 after treatment. Samples were analyzed by GSEA to identify significantly enriched gene sets. GSEA plots compared untreated Tert + / + With untreated G3 Tert - / - Mouse, FA-treated Tert + / + G3 Tert treated with FA - / - Mouse, FA-treated Tert + / + With unprocessed Tert + / + mice, and FA-treated G3Tert - / - With untreated G3 Tert - / - EMT (a) and TGFβ signaling pathway (b) in mice. The red to blue horizontal bars represent the ranked lists. Genes located in the center region of the bars show smaller gene expression differences between pairwise comparisons. Genes at the red edge of the bars show higher expression levels, while genes at the blue edge of the bars show lower expression levels. Red and blue arrows indicate upregulation and downregulation of pathways in pairwise comparisons, respectively. The false discovery rate (FDR) is annotated. Samples correspond to four independent Tert + / + 、G3 Tert - / - and FA-treated G3 Tert - / - Mice and three FA-treated Tert + / + Mouse kidney. c. 14 days after administration of a sublethal dose of FA, Tert + / +, Tert treated by FA + / + 、G3 Tert - / - and FA-treated G3 Tert - / - Relative expression of Tgfb1, Snail1, Snail2, Twist1, Zeb1, Zeb2, Loxl2, Cdh1, and Smad3 in mice. Representative images and quantification of immunohistochemical staining of dE-cadherin and phosphorylated SMAD3 (p-SMAD3). Inset: amplified p-SMAD3 staining images. Statistical analysis was performed using one-way ANOVA and post hoc Tukey test. Data are presented as mean ± sem. The number of mice analyzed for each genotype is indicated. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.

[0014] Figure 7 : Trf1 deficiency induces renal fibrosis. a. Schematic diagram of experimental method. b. Trf1 + / + and Trf1 flox / flox Representative images and quantification of Masson's trichrome, Sirius red, and SMA staining in mouse c.Trf1 + / + and Trf1 flox / flox Relative expression of Trf1 and mesenchymal markers Acta2 and Fn1 in mice. d.Trf1 + / + and Trf1 flox / flox Relative expression of EMT markers Tgfb1, Snail1, Snail2, Twist1, Zeb1, and Zeb2 in mice. Statistical analysis was performed using a two-tailed t-test. Data are presented as mean ± sem. The number of mice analyzed for each genotype is indicated. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.

[0015] Figure 8 : TERT activation in vitro rescues EMT phenotype. a, b. Wild-type PTC and G3 Tert transduced with empty (ineffective) vector or mTert-containing vector - / - Relative mRNA mTERT expression (a) and telomere length analysis (b) in PTCs. c. Terts from 10 to 11 weeks old transduced with empty (null) vector or mTert-containing vector + / + and G3 Tert - / -Immunofluorescence of E-cadherin, SMA, and Snail1 / Slug in PTCs of PTCs. Twenty micrographs were taken in each case. d. Relative mRNA Cdh1, Acta2, Vim, Col3a1, Col4a1, Tgfb1, Snail1, Snail2, and Zeb1 expression. Data are presented as mean ± sem. The number of mice analyzed for each genotype is indicated. Statistical analysis was performed using one-way ANOVA and post hoc Tukey's test. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.

[0016] Fig. 9 :Telomerase-deficient mice with short telomeres do not spontaneously develop renal fibrosis. a. Schematic diagram of the experimental method. bf.Tert + / + and G3Tert - / - Representative images and quantification of Masson's trichrome (b), Sirius red (c), PAS-amylase (d), SMA (e), and E-cadherin (f) in mice. gh.Tert + / + and G3Tert - / - Representative images and quantification of immunohistochemical staining of p21 (g) and CC3 (h) in mice. Insets show magnified images. Statistical analysis was performed using a two-tailed t-test. Data are presented as mean + / - SEM. The number of mice analyzed for each genotype is indicated.

[0017] Fig.10 : Blood parameters. Untreated and FA-treated Tert + / + and G3Tert - / - Serum creatinine (a) and blood urea nitrogen (BUN) (b) levels in mice. Blood samples were collected on days 2, 7, and 14. Mice were sacrificed on day 14. a. Statistical analysis was performed using two-way ANOVA and post hoc Bonferroni test. Data are presented as mean + / - SEM. The number of mice analyzed for each genotype is indicated. *p≤0.05; **p≤0.01; ***p≤0.001.

[0018] Fig.11 : Effects of short telomeres on cell cycle regulation. After 14 days of low-dose FA administration, the telomeres + / + , Tert treated by FA + / + 、G3Tert - / - G3Tert with FA treatment - / -Relative expression of CCnd1, CCnd2, CCnb1, and CCne1 in mice. Statistical analysis was performed using one-way ANOVA. Data are presented as mean + / - SEM. The number of mice analyzed for each genotype is indicated. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

[0019] Fig.12 :Effects of shorter telomeres on EMT-related genes. a. By comparing the results of 7-week-old and 47-week-old Terc + / + and G3Tert - / - Gene expression data obtained by RNA-seq of mouse kidney samples. b. Gene set enrichment analysis (GSEA) diagram of EMT pathway. The false discovery rate (FDR) is annotated. The samples correspond to five independent Terc + / + 、G3 Tert - / - Mouse kidney.

[0020] Fig.13 : Effects of shorter telomeres on renal progenitor cell genes. a. After 14 days of low-dose FA administration, Tert + / + , Tert treated by FA + / + 、G3Tert - / - G3Tert with FA treatment - / - Relative expression of Sox-9, Wt-1, Pax-2, Sall2, Acvr2b, and Klotho in mice. b. Representative images and quantification of Sox-9 immunohistochemical staining. Insets show magnified images. Statistical analysis was performed using one-way ANOVA. Statistical analysis was performed using one-way ANOVA. Data are presented as mean + / - SEM. The number of mice analyzed for each genotype is indicated. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

[0021] Fig.14 : Effects of shorter telomeres on Notch target genes. After 14 days of low-dose FA administration, Tert + / + , Tert treated by FA + / + 、G3Tert - / - G3Tert with FA treatment - / - Relative expression of Notch1, Notch2, Notch3, Jagged1, and Tfam in mice. Statistical analysis was performed using one-way ANOVA. Data are presented as mean + / - SEM. The number of mice analyzed for each genotype is indicated. *p≤0.05; **p≤0.01; ***p≤0.001.

[0022] Fig.15: TERT activation in vitro rescues the EMT phenotype. a, b. Microscopic bright field images of proximal tubule cell (PTC) cultures at day 8 (a) and day 14 (b) after transduction with empty vector or vector containing mTert. c Representative immunofluorescence images of E-cadherin, SMA and Tgfβ1. Twenty micrographs were taken in each case. Summary of the invention

[0023] In one aspect, the present invention provides a nucleic acid vector comprising a coding sequence for telomerase reverse transcriptase (TERT) for treating renal fibrosis associated with the presence of short telomeres. Preferably, TERT is encoded by a nucleic acid sequence comprising a sequence of SEQ ID NO:1 or SEQ ID NO:3. Preferably, TERT is encoded by a nucleic acid sequence consisting of a sequence of SEQ ID NO:1 or SEQ ID NO:3. Preferably, TERT comprises an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. Preferably, TERT consists of an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. Preferably, the nucleic acid sequence encoding TERT is operably linked to a regulatory sequence that drives expression of the coding sequence. Preferably, the vector is a non-integrating vector. Preferably, the vector is ribonucleic acid (RNA), preferably messenger RNA.

[0024] Preferably, the vector is a non-integrating vector based on an adeno-associated virus. Preferably, the vector is an adeno-associated virus-based vector derived from a serotype 9 adeno-associated virus (AAV9). Preferably, the capsid of the adeno-associated virus-based vector is made of the capsid protein of a serotype 9 adeno-associated virus (AAV9), and both ends of the nucleic acid sequence contained in the capsid are adjacent to the internal terminal repeat sequence corresponding to the serotype 2 adeno-associated virus. Preferably, the nucleic acid contained in the capsid includes a fragment encoding an amino acid sequence for encoding TERT. Preferably, the vector comprises a regulatory sequence, which is a constitutive promoter, preferably a cytomegalovirus (CMV) promoter.

[0025] In another aspect, the present invention provides a non-human animal characterized in that it exhibits a pathological condition of renal fibrosis, wherein the non-human animal is obtained or can be obtained when a sublethal dose of folic acid is administered to a non-human animal whose germ cells contain genetic inactivation of both alleles of the Tert gene.

[0026] Preferably, the animal is a mammal, preferably a rodent. The sublethal dose of folic acid is preferably a dose of up to 200 mg / kg body weight, preferably 125 mg / kg body weight.

[0027] Preferably, the folic acid is administered intraperitoneally. Preferably, the folic acid is administered to the animal between 4-10 weeks of age, preferably 6-8 weeks of age. Preferably, wherein the folic acid is administered once.

[0028] Preferably, the non-human animal whose germ cells comprise genetic inactivation of both alleles of the Tert gene (Tert- / -) is of the third generation (G3) of a Tert- / - pedigree. DETAILED DESCRIPTION

[0029] The discovery of the role of short telomeres in aplastic anemia and pulmonary fibrosis, thanks to the development of suitable mouse models, has opened the way for the development of potential therapeutic strategies for these diseases. However, for other complex diseases, such as renal fibrosis, the lack of suitable animal models has hampered the study of the role of short telomeres in these pathologies.

[0030] In this study, we aimed to investigate the role of short telomeres in renal fibrosis. To do this, it was necessary to develop an appropriate animal model. We first analyzed kidneys from wild-type mice, as well as mice lacking the catalytic subunit of telomerase, Tert, which had been bred for three generations (G3), hence G3 Tert. - / - Mouse ( Fig. 9 However, we found that wild-type (Tert + / + ) and G3 Tert - / - All mice showed grossly normal renal histology, with no evidence of glomerular or tubular defects and no accumulation of fibrosis or collagen fibers ( Fig. 9 b, c). Similarly, mice lacking the catalytic subunit of telomerase, Tert, did not show increased tubular damage or loss of renal brush border. - / - Normal kidneys of mice are consistent with age-matched Tert + / + No differences were found in the presence of activated fibroblasts, apoptosis, senescence, or expression of E-cadherin (a marker of EMT, associated with tissue fibrosis) compared to mice ( Figure 1 eh). These results conclude that telomerase-deficient mice do not spontaneously develop renal fibrosis per se, raising the question of whether other factors are required to promote the development of this pathology in mice with short telomeres. In this regard, since the incidence of renal fibrosis increases with age, we also questioned whether renal fibrosis could be caused by a combination of molecular and cellular aging events, such as the presence of short telomeres and exogenous insults to the kidney.

[0031] Folic acid (FA) induces interstitial fibrosis, but only at high doses. Intraperitoneal injection of high-dose FA (250 μg / g BW) into mice rapidly induces folate crystals and tubular necrosis in the acute phase (1-14 days) and patchy interstitial fibrosis in the chronic phase (28-42 days). However, lower doses of FA were not found to induce renal fibrosis in wild-type mice. Therefore, we aimed to investigate the effects of sublethal doses of FA on the renal function of 8-9-week-old Tert mice. + / + and G3 Tert - / - To this end, we first exposed 8-9 week old Tert mice to + / + and G3Tert - / - Mice received increasing doses of FA (50, 100, 125, and 250 mg kg-1 body weight; Figure 1 a) and selected the highest FA dose that did not induce renal fibrosis in wild-type mice. The results showed that 125 mg kg-1 was the maximum tolerated dose of FA that did not cause death in wild-type mice with normal telomere length ( Figure 1 We next investigated whether this dose of FA was insufficient to induce Tert + / + "We found that telomerase-deficient mice treated with sublethal doses of FA showed all the hallmarks of the human disease, including severe renal dysfunction, as evidenced by elevated levels of creatinine and urea in the blood."

[0032] Furthermore, to assess the contribution of dysfunctional telomeres to the induction of renal fibrosis, we used a second model of telomere dysfunction, namely the deletion of TRF1, a component of the telomere protection complex. Specifically, we used a mouse model in which tamoxifen treatment resulted in the deletion of Trf1 in all renal cells ( Figure 7 ). The results show that mice with telomere dysfunction due to Trf1 deficiency spontaneously develop renal fibrosis, highlighting the importance of proper telomere function in preventing fibrotic pathology.

[0033] In general, the present invention provides a suitable mouse model for studying renal fibrosis associated with telomere length. The mouse model is a key tool for understanding the role of short and dysfunctional telomeres and the resulting DNA damage in molecular events associated with fibrosis, particularly renal fibrosis. They will also allow the development of gene therapy approaches aimed at correcting the accumulation of very short telomeres associated with the condition.

[0034] In view of the above, in the first aspect, the present invention provides compositions and methods for treating and preventing conditions associated with short telomere length, particularly renal fibrosis, in subjects in need thereof. "Conditions associated with short telomere length" are characterized by accumulation of extremely short telomeres. In certain embodiments, the condition associated with short telomere length is characterized by mutations in one or more genes involved in telomere maintenance. Specific examples of such gene-based conditions include, but are not limited to, renal fibrosis, preferably renal fibrosis associated with telomere shortening. Short telomeres aggravate the epithelial-mesenchymal transition (EMT) program of the kidneys, and thus promote pathological scarring of renal tissue, i.e., fibrosis. The characteristic of renal fibrosis associated with telomere shortening is that short telomeres or dysfunctional telomeres are present due to gene mutations associated with telomere maintenance, wherein the most common mutations are genes encoding telomerase complex proteins (i.e., TERT, TERC, NOP10, DKC1, NHP2). Functional telomerase complexes and appropriate telomere capping structures formed by telomere protein complexes are necessary for the maintenance and capping of chromosome ends, respectively.

[0035] In some embodiments, renal fibrosis is characterized by abnormal production and deposition of extracellular matrix (ECM) proteins, which mainly occur in the renal interstitium and lead to structural damage, impaired renal function, and ultimately end-stage renal disease (ESRD). The clinical features of patients with renal fibrosis are swelling of the ankles, feet or hands, shortness of breath, fatigue, hematuria, insomnia, itchy skin, muscle cramps and headaches, etc. Renal fibrosis is a direct consequence of the limited regenerative capacity of the kidney after damage. In some embodiments, renal fibrosis is characterized by fibroblast activation and excessive production and deposition of extracellular matrix (ECM), which leads to renal parenchymal destruction, inflammatory and fibrotic reactions and decreased renal function. Please note that renal fibrosis is a synonym for kidney fibrosis.

[0036] Therefore, the present invention provides compositions and methods for treating a subject in need of a condition (preferably renal fibrosis) associated with short telomere length, including administering to the patient an agent that increases the patient's telomere length. The present invention also relates to methods for preventing the condition. "Prevention," "preventing," or "preventing" or any other similar terms include, but are not limited to, reducing, reducing or improving the risk of symptoms, illnesses, conditions, or diseases, and protecting animals from symptoms, illnesses, conditions, or diseases. Preventive measures may be applied or applied prophylactically. "Treatment," "treatment," or "treatment" or any other similar terms include, but are not limited to, inhibiting, slowing down, stopping, reducing, improving, or reversing the progression or severity of existing symptoms, clinical signs, illnesses, conditions, or diseases. Treatment may be applied or applied in a therapeutic manner.

[0037] "Subject in need" refers herein to a subject suffering from a condition in which the pathology is prematurely developed due to a defect in the regeneration capacity of renal tissue. In certain embodiments, the subject in need of the treatment exhibits a fibrotic response, preferably a renal fibrotic response, and / or decreased renal function. In some embodiments, the subject in need of the treatment exhibits a disease or condition that suggests or ultimately leads to renal fibrosis, such as glomerulosclerosis, renal interstitial fibrosis, diabetes, hypertension, infectious glomerulonephritis, renal vasculitis, ureteral obstruction, genetic alteration, autoimmune disease, or any combination thereof. Preferably, the subject in need of the treatment suffers from renal fibrosis, preferably renal fibrosis associated with telomere shortening. The term "patient" or "subject" is considered herein as a synonym and refers to a mammal. In certain embodiments, the patient is a rodent, a primate, a human, an ungulate, a cat, a dog, a mouse, a rat, a rabbit, a pig, a horse, a sheep, a cattle, a domestic cat or a domestic dog, or other domestic pets or domesticated mammals. In a preferred embodiment, the patient or subject in need is a human.

[0038] Compositions and methods

[0039] In one embodiment, the agent prevents degradation of chromosome ends. In one embodiment, the agent increases the activity of telomerase reverse transcriptase (TERT). In one embodiment, the treatment method is a gene therapy method, comprising administering to the patient a nucleic acid vector comprising a coding sequence for telomerase reverse transcriptase (TERT).

[0040] In certain embodiments, the TERT sequence used in the gene therapy vector is derived from the same species as the subject. For example, gene therapy for humans will be performed using human TERT sequences. In one embodiment, TERT is encoded by the nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3 (human TERT variants 1 and 2), or is an active fragment or functional equivalent of SEQ ID NO:1 or SEQ ID NO:3. The polypeptide sequence encoded by SEQ ID NO:1 is shown in SEQ ID NO:2. The polypeptide encoded by SEQ ID NO:3 is shown in SEQ ID NO:4. "Functional equivalents" as used herein refer to nucleic acid molecules encoding polypeptides having TERT activity or polypeptides having TERT activity. Compared to TERT encoded by SEQ ID NO:1 or SEQ ID NO:3, functional equivalents may exhibit 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, 100% or more activity. In one embodiment, TERT is encoded by a nucleic acid sequence comprising or consisting of a nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:3. Functional equivalents may be artificial or naturally occurring. For example, naturally occurring TERT sequence variants in a population fall within the scope of functional equivalents. TERT sequences derived from other species also fall within the scope of the term "functional equivalents", in particular the mouse TERT sequence given in SEQ ID NO:5. In a specific embodiment, a functional equivalent is a nucleic acid having a nucleotide sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identical to SEQ ID NO:1 or SEQ ID NO:3. In a further embodiment, a functional equivalent is a polypeptide having an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identical to SEQ ID NO: 2 or SEQ ID NO: 4. In one embodiment, TERT comprises or consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. For functional equivalents, sequence identity should be calculated along the entire length of the nucleic acid. Compared to SEQ ID NO: 1 or SEQ ID NO: 3, a functional equivalent may comprise one or more, for example 2, 3, 4, 5, 10, 15, 20, 30 or more nucleotide insertions, deletions and / or substitutions.The term "functional equivalent" also encompasses nucleic acid sequences encoding TERT polypeptides having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% sequence identity to the sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4, but having little homology to the nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3 due to the degeneracy of the genetic code. Sequence identity can be calculated by any of a variety of methods in the art, including, for example, BLAST and variations of these alignment programs.

[0041] As used herein, the term "active fragment" refers to a nucleic acid molecule encoding a polypeptide having TERT activity or a polypeptide having TERT activity, but it is a fragment of the nucleic acid shown in SEQ ID NO: 1 or SEQ ID NO: 3 or the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4. The active fragment can be of any size as long as the TERT activity is retained. Along the alignment length between the shorter fragment and SEQ ID NO: 1-4, the identity of the fragment to SEQ ID NO: 1-4 is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 100%.

[0042] The fusion protein comprising these fragments can be included in the nucleic acid carrier required for implementing the present invention. For example, without compromising the ability of the polypeptide fragment to correctly fold and show biological activity, additional 5, 10, 20, 30, 40, 50 or even 100 amino acid residues from the polypeptide sequence or homologous sequence can be included at the C-terminal and / or N-terminal ends.

[0043] In one embodiment, the therapeutic method is a gene therapy method and / or the nucleic acid carrier used is a gene therapy carrier. Gene therapy methods and carriers are well known in the art and generally include delivering a nucleic acid encoding a therapeutically active protein to a subject. Nucleic acids can be delivered in a variety of ways and forms, including delivering naked deoxyribonucleic acid (DNA) such as plasmids or minicircles, delivering ribonucleic acids (RNA) such as messenger RNA, using liposomes or cationic polymers or other engineered nanoparticles containing nucleic acids, or viral carriers that encapsidate nucleic acids.

[0044] In a further embodiment, gene therapy is achieved using stable transformation of an organism with an inducible expression system. Suitable inducible expression systems are known in the art and include CRE-LOX recombinase-based systems for mice and tetracycline-regulated systems that can be used to treat human subjects.

[0045] In one embodiment, the gene therapy vector is a ribonucleic acid (RNA) vector comprising a coding sequence of telomerase reverse transcriptase (TERT) as defined above or consisting thereof. In some embodiments, the RNA nucleic acid vector is delivered in a naked (i.e., unshielded RNA) form. In some other embodiments, the RNA nucleic acid vector is modified to prevent degradation by nucleases. The modification includes chemical modifications of the RNA structure, such as modifications made at the 2' position, phosphate bonds, and / or nucleobases. Other modifications include encapsidation of the RNA nucleic acid vector into nanoparticles, polymers, endosomes, lipids, and lipid-like particles or other delivery vehicles (e.g., viruses). The nanoparticle encapsulation of RNA physically protects the nucleic acid from degradation, and, depending on specific chemical properties, can contribute to cellular absorption and endosome escape. Polymers include poly (β-amino esters), poly-L-lysine, polyamidoamine, and polyethyleneimine, as well as naturally occurring polymers such as chitosan, which have all been applied to RNA delivery. Chemically defined delivery approaches involve the direct conjugation of biologically active ligands (e.g., N-acetylgalactosamine, cholesterol, vitamin E, antibodies, peptides) to RNA, allowing it to enter target cells.

[0046] Preferably, the RNA nucleic acid carrier is a single-stranded RNA molecule, more preferably a messenger RNA (mRNA) carrier. The delivery of therapeutic mRNA carriers is facilitated by maximizing the translation and stability of mRNA carriers, preventing their immunostimulatory activity, and developing in vivo delivery technologies. In some embodiments, the mRNA carrier is modified to improve the efficacy of in vivo delivery. In one embodiment, the mRNA carrier is modified to include the incorporation of a 5′ cap and / or a 3′ poly (A) tail to achieve efficient translation and extend the half-life of mature mRNA. Cap analogs such as ARCA (anti-reversal cap analog) and a poly (A) tail of 120–150 bp can also be used. Also included are novel cap analogs, such as 1,2-dithiodiphosphate-modified caps, which have the ability to resist RNA decapping complexes. So-called codon optimization is also beneficial to improve the efficiency of protein synthesis and limit the instability of rare codons to mRNA. Similarly, the level of protein product can be increased by modifying the 3′ and 5′ untranslated regions (UTRs) to include sequences responsible for recruiting RNA binding proteins (RBPs). N1-methyl-pseudouridine base modification is often used to mask the immunostimulatory activity of mRNA.

[0047] In one embodiment, the regulatory sequence operably linked to the TERT coding sequence is a cytomegalovirus promoter (CMV), although other suitable regulatory sequences are also known to those skilled in the art. In other embodiments, the regulatory sequence operably linked to the TERT coding sequence is a kidney-specific promoter. In a preferred embodiment, the coding sequence of the telomerase reverse transcriptase (TERT) gene contained in the RNA nucleic acid carrier is operably linked to a CMV or kidney-specific promoter, wherein the RNA nucleic acid carrier also includes a poly (A) sequence located at the end of the coding sequence of the telomerase reverse transcriptase (TERT) gene.

[0048] In one embodiment, the gene therapy vector is a viral vector. Viral gene therapy vectors are well known in the art. Vectors include integrating vectors and non-integrating vectors, such as vectors based on retroviruses, adenoviruses (AdV), adeno-associated viruses (AAV), retroviruses, poxviruses, alphaviruses and herpesviruses. It seems particularly advantageous to use non-integrating viral vectors (such as AAV). On the one hand, this is because non-integrating vectors do not cause any permanent genetic modification. Secondly, the vector targets adult tissues, thereby avoiding the subject from being affected by constitutive telomerase expression in the early stages of development. In addition, non-integrating vectors effectively combine safety mechanisms to avoid excessive proliferation of TERT expressing cells. If cells begin to proliferate rapidly, they will lose the vector (and thus lose the expression of telomerase).

[0049] Specific examples of suitable non-integrating vectors include vectors based on adenovirus (AdV), in particular enterovirus, adeno-associated virus (AAV), integrase-deficient lentivirus, poxvirus, alphavirus and herpes virus. Preferably, the non-integrating vector used in the present invention is a non-integrating vector based on adeno-associated virus, similar to a natural adeno-associated virus particle.

[0050] Vectors derived from adeno-associated viruses (AAV) have become one of the preferred vectors for many gene transfer applications due to their many desirable properties, including the ability to efficiently transduce a wide range of tissues, poor immunogenicity, and excellent safety profile, with no toxicity in many preclinical models. AAV vectors transduce post-mitotic cells and can maintain long-term gene expression (up to several years) in small and large animal disease models. The safety and efficacy of AAV gene transfer has been extensively studied in humans, with encouraging results in the liver, muscle, central nervous system, and retina.

[0051] AAV preferentially targets post-mitotic tissues, which are thought to be more resistant to cancer than highly proliferative tissues. Examples of non-integrating vectors based on adeno-associated viruses include vectors based on any AAV serotype (i.e., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and pseudotyped AAV). Tissue specificity is determined by the capsid serotype. Pseudotyping and capsid engineering of AAV vectors to change their tropism range may be very important for their use in therapy.

[0052] AAV2 is the best characterized serotype in gene transfer studies in humans and experimental models. AAV2 exhibits a natural tropism for skeletal muscle, neurons, vascular smooth muscle cells, and hepatocytes. Therefore, AAV2 is a good choice of vector for targeting these tissues, particularly when using the methods or vectors of the invention to treat a condition associated with one of these tissues. For example, treatment of neuromuscular degeneration can target skeletal muscle and / or neurons in this manner.

[0053] Newly isolated serotypes, such as AAV7, AAV8, and AAV9 have been successfully used in preclinical studies, and depending on the target tissue and route of administration, long-term expression of therapeutic genes is possible. In addition, the use of non-human serotypes (such as AAV8 and AAV9) may help overcome these immune responses in subjects, and clinical trials have just begun (ClinicalTrials.gov Identifier: NCT00979238).

[0054] Taken together, these encouraging data suggest that AAV vectors are useful tools for treating human disease with a high degree of safety and efficacy.

[0055] The selection of adeno-associated viruses with broad tropism, such as those derived from serotype 9 adeno-associated virus (AAV9), is particularly advantageous when treating conditions associated with short telomere length. AAV9 viruses have demonstrated efficient transduction in a wide range of tissues, with high tropism for liver, heart, and skeletal muscle, thus enabling the beneficial effects of gene therapy to be achieved in more tissues. In addition, AAV9 vectors have the unique ability to cross the blood-brain barrier and can target the brain after intravenous injection into adult mice and cats (Foust et al Nature biotechnology 2009).

[0056] One aspect of the present invention provides a system in which the capsid (which is the part of the virus that determines the tropism of the virus) of an adeno-associated virus-based vector is made of the capsid protein of serotype 9 adeno-associated virus (AAV9). In one embodiment of the viral vector used in the present invention, the polynucleotide sequence packaged in the capsid is flanked by internal terminal repeats (ITRs) of adeno-associated viruses, preferably internal terminal repeats (ITRs) of serotype 2 that have been extensively characterized in the art and show coding sequences located between ITRs. As described above, the nucleic acid preferably encodes a functional TERT polypeptide. In one embodiment, the regulatory sequence operably linked to the TERT coding sequence is a cytomegalovirus promoter (CMV), although other suitable regulatory sequences are also known to those skilled in the art. In another embodiment, the regulatory sequence operably linked to the TERT coding sequence is a kidney-specific promoter.

[0057] When treating conditions associated with short telomere length, it is advantageous to target the affected tissue for treatment. Therefore, the AAV serotype of the capsid protein of the gene therapy vector can be selected based on the desired site of gene therapy. If the target tissue is skeletal muscle, for example, when treating loss of neuromuscular coordination, viral vectors based on AAV1 and AAV6 can be used. Both of these serotypes have higher muscle transfection efficiency than other AAV serotypes.

[0058] Alternatively, other viral vectors may be used in the present invention. Any vector suitable for gene therapy may be used in the present invention. Heilbronn & Weger (2010) Handb Exp Pharmacol. 197: 143-70 provides a review of viral vectors for gene therapy.

[0059] According to all the above discussions, a vector containing a telomerase reverse transcriptase (TERT) coding sequence suitable for gene therapy is an important point for putting the present invention into practice. Suitable gene therapy vectors include any type of particles, which contain a polynucleotide fragment encoding a telomerase reverse transcriptase (TERT) protein operably linked to a regulatory element (e.g., a promoter), which allows the expression of a functional TERT protein exhibiting telomerase reverse transcriptase activity in a target cell. Preferably, TERT is encoded by a nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3, or TERT is an active fragment or functional equivalent of TERT. The term gene therapy vector includes within its scope naked DNA molecules, such as plasmids or minicircles, i.e., circular DNA molecules that do not contain bacterial DNA sequences, provided that the TERT coding sequence and its linked regulatory elements are inserted into the plasmid, as well as more complex systems, such as particles (virions) having a virion structure comprising at least a capsid and at least a polynucleotide sequence, the size of which allows the polynucleotide sequence to be packaged in the capsid in a manner similar to the natural genome of the capsid-derived virus. The polynucleotide sequence must include the region where the TERT coding sequence and its linked regulatory elements are inserted, so that after the virus particles infect cells, the telomerase reverse transcriptase protein can be expressed from the polynucleotide sequence.

[0060] In one embodiment, the gene therapy vector suitable for the present invention is a non-integrating vector, such as a non-integrating vector based on an adeno-associated virus. For the purposes of the present invention, the selection of non-integrating vectors seems particularly advantageous because they do not result in any permanent genetic modification. In addition, as previously mentioned, such vectors contain a safety mechanism to avoid excessive proliferation of TERT-expressing cells, and if the cells begin to proliferate rapidly, the cells will lose the vector.

[0061] It is preferred to use an adeno-associated virus vector derived from serotype 9 adeno-associated virus (AAV9) because this can achieve beneficial effects in more tissues (see above). In a particularly preferred embodiment, the regulatory sequence operably connected to the TERT coding sequence is a cytomegalovirus promoter (CMV). The nucleic acid sequence encoding TERT is operably connected to a regulatory sequence that drives the expression of the coding sequence. As used herein, the term "regulatory element" refers to a nucleic acid sequence that acts as a promoter, i.e., a nucleic acid sequence that regulates the expression of a nucleic acid sequence operably connected to a promoter. Such "regulatory elements" or "promoters" can control the expression of the connected nucleic acid sequence in a constitutive or inducible manner. The regulatory sequence can be a constitutive promoter. An example of a regulatory sequence as a constitutive promoter is a cytomegalovirus (CMV) promoter.

[0062] After gene therapy according to the present invention, expression of TERT persists for months to years. In one embodiment of the invention, the subject is treated once. In an alternative embodiment, the subject is first treated and then treated again once the level of TERT expression has dropped by about 50% relative to the level achieved immediately after treatment. If necessary, the treatment can be repeated using the same or alternative vector to maintain the reduction of age-related conditions, for example once a year, once every five years, or once every ten years. When administering a second or subsequent dose, it may be necessary to use a different gene therapy vector, for example, when using an AAV-based vector, the second and subsequent administrations may be vectors having a capsid derived from a different serotype than that used for the first administration.

[0063] The therapeutic methods of the present invention have the effect of treating and / or preventing conditions associated with short telomere length. Therefore, in another aspect, the present invention relates to a gene therapy method or the use of a nucleic acid vector as described above, which is used to treat or prevent renal fibrosis, preferably renal or fibrosis associated with short telomere length, in a subject in need thereof.

[0064] The therapeutic effect of the condition associated with short telomere length can be measured by various methods known in the art. In one embodiment, the effectiveness of the treatment is measured by the increase in the life span of the treated patient with the condition associated with short telomere length compared to the expected life span of an untreated patient with the same condition. In certain embodiments, the life span is extended by 5%, 10%, 15%, 20% or more relative to the expected life span of a patient with the same condition. In one embodiment, the effectiveness of the treatment is measured by the delay or prevention of renal failure in a treated patient with a condition associated with short telomeres compared to the expected onset of renal failure in an untreated patient with the same condition. In certain embodiments, the delayed onset of bone marrow failure in a treated patient with a condition associated with short telomere length is extended by 5%, 10%, 15%, 20% or more relative to the expected onset of renal failure in an untreated patient with the same condition.

[0065] In one embodiment, the effectiveness of the treatment is measured by the overall health of the treated patient with a condition associated with short telomeres (preferably renal fibrosis) compared to the overall health of an untreated patient with the same condition. The overall health can be determined by measuring the physical attributes associated with a specific condition. Therefore, the improvement in overall health can be determined by the reduction of the physical attributes associated with a specific condition exhibited by the treated patient. In one embodiment, the improvement in overall health is measured by determining the estimated glomerular filtration rate (eGFR) and / or albuminuria (ACR). A glomerular filtration rate (GFR) of 60 or more belongs to the normal range. A GFR below 60 may mean kidney disease. A GFR of 15 or less may mean kidney failure. A standardized albumin to creatinine ratio (ACR) test shows whether you have albumin in your urine. The normal amount of albumin in your urine is less than 30 mg / g. Even if your GFR value is above 60, any value above 30 mg / g may mean that you have kidney disease. In certain embodiments, the glomerular filtration rate of a treated patient is increased by 5%, 10%, 15%, 20% or more compared to the glomerular filtration rate of an untreated patient with the same condition.

[0066] The effectiveness of treatment can also be measured by directly measuring telomere length in patient samples. For example, telomere length can be measured in samples taken from patients using standard hybridization techniques such as fluorescence in situ hybridization (FISH), quantitative fluorescence in situ hybridization (Q-FISH), or high-throughput quantitative fluorescence in situ hybridization (HTQ-FISH). Suitable samples for telomere analysis include blood, urine, or tissue biopsies, such as kidney biopsies.

[0067] In a specific embodiment, samples are collected from patients undergoing treatment throughout the course of treatment so that the absolute telomere length and the rate of telomere shortening during treatment can be determined. Samples can be collected daily during treatment or at longer intervals. In one embodiment, samples are collected weekly, every two weeks, every three weeks, every four weeks, every five weeks, every six weeks or more. Comparison of telomere length can be measured by comparing the fraction of short telomeres collected from patient samples. In one embodiment, the fraction of short telomeres is the portion of the telomere whose intensity is lower than the average intensity of the sample as measured by in situ hybridization techniques (such as FISH or Q-FISH). In one embodiment, the fraction of short telomeres is the portion of the telomere whose intensity is 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40% or more lower than the average intensity of the sample. In a specific embodiment, the fraction of short telomeres is the portion of the telomere that exhibits an intensity that is 50% or more lower than the average intensity of the sample.

[0068] In another embodiment, the share of short telomeres is the portion of telomeres below a certain length, such as 8kb, 7kb, 6kb, 5kb or less. In one embodiment, the share of short telomeres is the portion of telomeres that is 8kb or less. In another embodiment, the share of short telomeres is the portion of telomeres that is 7kb or less. In another embodiment, the share of short telomeres is the portion of telomeres that is 6kb or less. In another embodiment, the share of short telomeres is the portion of telomeres that is 5kb or less. In another embodiment, the share of short telomeres is the portion of telomeres that is 4kb or less. In another embodiment, the share of short telomeres is the portion of telomeres that is 3kb or less.

[0069] In one embodiment, the effectiveness of the treatment is measured by a reduction in the fraction of short telomeres in a sample collected from a patient with a condition associated with short telomere length, preferably renal fibrosis, compared to a control sample. In one embodiment, the fraction of short telomeres in a sample collected from a treated patient is reduced by 10%, 20%, 30%, 40%, 50%, 60%, 70% or more compared to a control sample. In one embodiment, the control sample is a sample collected from the same patient before treatment or in the early stages of treatment. In another embodiment, the control sample is a sample collected from a patient with the same condition but not treated.

[0070] In another aspect, the present invention is applied to a subject by administering a pharmaceutical composition comprising an effective amount of any one of the gene therapy vectors compatible with the above invention.

[0071] A "pharmaceutical composition" is intended to include an active agent in combination with an inert or active carrier, such that the composition is suitable for in vitro, in vivo or ex vivo diagnostic or therapeutic use.

[0072] "Composition" is intended to mean a combination of an active agent and another inert (e.g., a detectable agent or label) or active compound or composition. An "effective amount" is an amount sufficient to produce a beneficial or desired result. An effective amount can be administered in one or more administrations, applications or dosages.

[0073] They typically include components in addition to the active ingredient (eg, gene therapy vector), for example, they typically include one or more pharmaceutically acceptable carriers and / or excipients.

[0074] The composition is generally administered to the subject in an aqueous form. However, prior to administration, the composition may be in a non-aqueous form. For example, although some viral vectors are manufactured in an aqueous form and then also filled, distributed and administered in an aqueous form, other viral vectors are lyophilized during the manufacturing process and reconstituted into an aqueous form when used. Therefore, the composition of the present invention can be dried, for example, as a lyophilized preparation. The composition may contain a preservative, such as thimerosal or 2-phenoxyethanol. However, it is preferred that the composition should be substantially free of (i.e., less than 5 μg / m'í') mercury substances, such as thimerosal.

[0075] To control tonicity, physiological salts, such as sodium salts, are preferably added. Sodium chloride (NaCl) is preferred, and its concentration may be between 1 and 20 mg / ml, such as about 10+2 mg / ml NaCl. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium hydrogen phosphate dihydrate, magnesium chloride, calcium chloride, and the like.

[0076] The osmolarity of the composition is generally between 200 mOsm / kg and 400 mOsm / kg, preferably between 240 and 360 mOsm / kg, more preferably in the range of 290 to 310 mOsm / kg.

[0077] The composition may include one or more buffers. Typical buffers include: phosphate buffer; Tris buffer; borate buffer; succinate buffer; histidine buffer (especially containing aluminum hydroxide adjuvant); or citrate buffer. The content of the buffer is usually in the range of 5-20 mM.

[0078] The composition may include materials for a single administration, or may include materials for multiple administrations (i.e., a "multi-dose" kit). A preservative is preferably added in a multi-dose arrangement. As an alternative (or in addition) to adding a preservative to a multi-dose composition, the composition may be contained in a container having a sterile connector for removing the material.

[0079] The composition of the invention for use in humans is usually administered in a dosage volume of about 0.5 ml, although children may be administered half the dose (ie about 0.25 ml).

[0080] In addition to the treatment methods described herein, the present invention also provides a nucleic acid sequence encoding TERT for treatment. The present invention also provides a nucleic acid vector comprising a telomerase reverse transcriptase (TERT) coding sequence for a treatment method, and a gene therapy vector comprising a telomerase reverse transcriptase (TERT) coding sequence for a treatment method. Specifically, the therapy can treat or prevent conditions associated with short telomere length. As described in the treatment method, the TERT nucleic acid sequence can be a sequence described in SEQ ID NO: 1 or SEQ ID NO: 3, or a fragment or functional equivalent thereof. The TERT protein can have a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 4, or a fragment or functional equivalent thereof.

[0081] The following embodiments are also derived from the first aspect and are included herein:

[0082] 1. A method for treating a patient suffering from renal fibrosis associated with short telomere length, comprising administering to the patient a nucleic acid vector comprising a telomerase reverse transcriptase (TERT) coding sequence.

[0083] 2. The method of 1, wherein TERT is encoded by a nucleic acid sequence comprising a sequence that is at least 90% identical to the sequence of SEQ ID NO: 1 or SEQ ID NO: 3.

[0084] 3. The method of 1 or 2, wherein TERT is encoded by a nucleic acid sequence comprising SEQ ID NO: 1 or SEQ ID NO: 3.

[0085] 4. The method according to any one of 1 to 3, wherein TERT is encoded by a nucleic acid sequence consisting of SEQ ID NO: 1 or SEQ ID NO: 3.

[0086] 5. The method of any one of 1-4, wherein TERT comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

[0087] 6. The method of any one of 1-5, wherein TERT comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

[0088] 7. The method of any one of 1-6, wherein TERT consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

[0089] 8. The method of any one of 1-7, wherein the nucleic acid sequence encoding TERT is operably linked to a regulatory sequence that drives expression of the coding sequence.

[0090] 9. The method of any one of 1-8, wherein the vector is a non-integrating vector.

[0091] 10. The method of any one of 1-9, wherein the vector is an adeno-associated virus-based non-integrating vector or an RNA vector.

[0092] 11. The method of any one of 1-10, wherein the vector is an adeno-associated virus-based vector derived from serotype 9 adeno-associated virus (AAV9).

[0093] 12. The method of 11, wherein the capsid of the adeno-associated virus-based vector is composed of the capsid protein of serotype 9 adeno-associated virus (AAV9), and both ends of the nucleic acid sequence contained in the capsid are adjacent to the internal terminal repeat sequence corresponding to serotype 2 adeno-associated virus.

[0094] 13. The method of 12, wherein the nucleic acid contained in the capsid includes a fragment encoding an amino acid sequence for encoding TERT.

[0095] 14. The method of any one of 1 to 13, wherein the vector comprises a regulatory sequence which is a constitutive promoter.

[0096] 15. The method of 14, wherein the regulatory sequence is a cytomegalovirus (CMV) promoter.

[0097] 16. The method of any one of 1-15, wherein the renal fibrosis associated with short telomere length is characterized by mutations in one or more genes involved in telomere maintenance.

[0098] Non-human gene knockout animal models

[0099] In a second aspect, the present invention also provides a non-human gene knockout animal model, characterized in that it exhibits a pathological condition of renal fibrosis, wherein the non-human animal is obtained or obtainable when a sublethal dose of folic acid is administered to a non-human gene knockout animal comprising at least one, preferably two, inactivated Tert gene alleles. Herein, "at least one, preferably two, inactivated Tert gene alleles" refers to a process in which the sequence of one or two alleles of the Tert gene is changed, thereby causing the allele to lose its biological function. The change in the allele sequence can be achieved by inserting nucleotides into the allele or by partially or completely deleting the nucleotides of the allele.

[0100] Specifically, a knockout mutation occurs in the Tert gene in a non-human knockout animal model, causing Tert to be knocked out. The term "knockout animal" as used herein refers to a non-human animal, preferably a mammal, which carries one or more genetic manipulations that cause the inactivation of the Tert gene (only one allele of the gene, or preferably two alleles). The knockout mutation of one or two alleles of the Tert gene can be present in the reproductive cells, somatic cells, or both of the animals (that is, the knockout mutation of the Tert gene is present in all cells of the animal). "Reproductive cells" herein refer to reproductive cells or gametes (eggs and sperm). "Somatic cells" herein refer to cells that form the body of a multicellular organism except reproductive cells or gametes.

[0101] In a preferred embodiment, the non-human knockout animal is a rodent, such as a mouse or a rat. The first generation of male animals is called G0, and the first, second, and third generations are called G1, G2, and G3, respectively. Preferably, the non-human knockout animal is a Tert - / - The third generation (G3) or subsequent generations (G4, G5, etc.) of the knockout animal lineage. Preferably, the non-human animal model is a G3 Tert - / - Mouse. Expression "G3Tert - / - " refers herein to a third generation animal, preferably a mouse, comprising an inactivation of both alleles of the Tert gene, preferably wherein the inactivation is hereditary, i.e. it is present in the germ cells of the animal. In order to generate a population of Tert - / - Animals, heterozygous animals Tert + / - Crosses were performed to produce homozygous animals Tert - / - , for further phenotypic analysis. Knockout technology is well known in the art.

[0102] The embryonic cells of each developmental stage can be used to introduce genes, to produce knock-out animals. Different methods are adopted according to the developmental stage of embryonic cells. The embryonic stem cell (ES) of this transfection can be colonized in embryo after being introduced into the blastocoel of blastocyst stage embryo, and forms the germ cell of the resulting chimeric animal. Before the ES cell of transfection is introduced into the blastocoel, various selection schemes can be carried out to the ES cell of transfection, to enrich the share (if the knock-out gene provides the means of this selection) of the ES cell that has been integrated into the knock-out gene. Alternatively, PCR can be used to screen the ES cell that has been integrated into the knock-out.

[0103] In addition, retroviral infection can also be used to introduce knockout genes into non-human animals. Developing non-human embryos can be cultured in vitro to the blastocyst stage. During this period, blastomeres may become targets for retroviral infection. The zona pellucida is removed by enzymatic treatment to achieve efficient infection of blastomeres. The viral vector system used to introduce knockouts is usually a replication-defective retrovirus carrying knockouts. Transfection can be easily and efficiently obtained by culturing blastomeres on a monolayer of cells that produce viruses. Alternatively, infection can be performed at a later stage. Viruses or cells that produce viruses can be injected into the blastocyst cavity. Most of the first generations will be mosaics of knockout genes because incorporation occurs only in a small fraction of cells that form knockout animals. In addition, the first generation can contain various retroviral insertions of knockout genes at different locations in the genome, and these retroviral insertions are usually separated in the offspring. In addition, knockout genes can be introduced into the germline by intrauterine retroviral infection of mid-gestation embryos. Other methods known to those skilled in the art for producing knockout animals using retroviruses or retroviral vectors include microinjection of retroviral particles or mitomycin C-treated cells producing retroviruses into the perivitelline space of fertilized eggs or early embryos.

[0104] Once the first generation of animals is born, they can be bred, inbred, outbred or crossbred to produce a population of specific animals. Knockout animals are screened and evaluated to select animals with a phenotype of interest. Preliminary screening can be performed by analyzing animal tissues using, for example, Southern blot analysis or PCR techniques to verify whether gene knockout occurs. Knockout animals can be identified by using techniques to evaluate the expression level of TERT mRNA in knockout animal tissues, including but not limited to Northern blot analysis, in situ hybridization analysis and reverse transcription PCR (rt-PCR) of tissue samples obtained from animals. Specific antibodies for Tert proteins or antibodies with labels such as EGFP can be used to perform immunocytochemical assessments on samples of suitable tissues. Knockout non-human mammals can be further characterized to identify animals with phenotypes that can be used in the present invention. Specifically, once a sublethal dose of FA is administered, knockout non-human mammals with one or two Tert alleles inactivated can be screened according to the presence of renal pathology or fibrosis.

[0105] As shown in the following example, G3 Tert - / -Non-human knockout mice will only become a non-human animal model of renal fibrosis when a sublethal dose of FA is administered. Therefore, it is worth noting that the non-human animal model according to the second aspect is characterized in that it is a knockout of at least one, preferably two alleles of the gene encoding the telomerase catalytic subunit Tert, and is further characterized in that it exhibits a pathological condition of renal fibrosis after treatment with a sublethal dose of folic acid. "Sublethal dose" herein refers to a dose that does not induce renal fibrosis in wild-type mice. In one embodiment, the sublethal dose is less than 250 mg / kg body weight. Preferably, the dose range of FA administered to non-human animals is 50 to 200 mg / kg, more preferably 50-175 mg / kg, 50-150 mg / kg, 100-150 mg / kg, and most preferably about 125 mg / kg body weight. Preferably, the dose of FA is a dose of up to 200 mg / kg body weight, more preferably a dose of up to 125 mg / kg body weight.

[0106] The non-human knockout animal model for renal fibrosis is further characterized in that, after administration of a sublethal dose of FA, creatinine and BUN levels in the blood are elevated. Further, the non-human knockout animal model exhibits increased renal fibrosis (detected by Masson's trichrome staining) and increased tubular damage (determined by increased PAS+D staining), as shown in the Examples below.

[0107] In one embodiment, the dose of FA is administered only once, preferably at the beginning of the study. In another embodiment, FA is administered several times. In some other embodiments, FA is administered once a day for several days (e.g., once a day, once every two days, once a week, once every two weeks, or once a month). In some embodiments, the dose of FA is administered systemically, preferably intraperitoneally or intravenously.

[0108] The non-human knockout animal to which FA is administered to produce the non-human animal model of the second aspect is 4-10 weeks old, preferably 6-8 weeks old.

[0109] In a third aspect, the present invention provides a non-human knockout animal model for studying and / or evaluating renal fibrosis associated with the presence of short telomeres, wherein the non-human knockout animal is as defined in the second aspect or any embodiment thereof.

[0110] In a fourth aspect, the present invention provides a method for generating a non-human knockout animal model for evaluating renal fibrosis associated with the presence of short telomeres, the method comprising the steps of:

[0111] i) providing a non-human animal, preferably a rodent, characterized in that one allele, preferably two alleles, of the gene encoding the catalytic subunit Tert of telomerase are knocked out, the non-human animal preferably being from the third generation (G3 Tert- / - non-human animal), as defined in the second aspect or any embodiment thereof, and

[0112] ii) administering i) at least one sublethal dose of folic acid to a non-human animal also as defined in the second aspect or any embodiment thereof.

[0113] In a fifth aspect, the present invention provides a non-human knockout animal model for evaluating renal fibrosis associated with the presence of short telomeres, wherein the non-human animal is obtained according to the method of the fourth aspect or any embodiment thereof.

[0114] In a sixth aspect, the present invention provides a method for assessing renal fibrosis associated with the presence of short telomeres, wherein the method comprises using a non-human animal model as defined in the second aspect or any embodiment thereof.

[0115] In a seventh aspect, the present invention provides a non-human animal model as defined in the second aspect or any embodiment thereof, for screening a method for improving, treating or preventing a compound associated with renal fibrosis with short telomeres. In a preferred embodiment, the method comprises the following steps:

[0116] i) administering a compound to a non-human animal model of renal fibrosis associated with the presence of short telomeres as defined in the second aspect or any embodiment thereof, ii) detecting or evaluating symptoms of renal fibrosis, and

[0117] iii) comparing the symptoms of renal fibrosis with those of an animal group not administered with the compound, and selecting a compound that improves the symptoms, and / or

[0118] iv) Comparison of renal fibrosis symptoms before and after administration of the test compound.

[0119] In the eighth aspect, the present invention provides a method for screening a test compound for renal fibrosis associated with the presence of short telomeres, wherein the test compound is administered to a non-human knockout animal model as defined in the second aspect or any of its embodiments, wherein any changes in life expectancy or symptoms associated with renal fibrosis associated with the presence of short telomeres are measured and evaluated, and wherein a test compound that improves the changes is determined to have a therapeutic effect. A specific embodiment of the screening method of the seventh or eighth aspect comprises the following steps: wherein tissues, organs or cells from the non-human knockout animal model are contacted with a test compound, and changes in the tissues, organs or cells are measured and evaluated to determine which test compound causes improvement and therefore has a therapeutic effect.

[0120] The test compound that is found to have a therapeutic effect on renal fibrosis associated with the presence of short telomeres, which can be obtained by the screening method disclosed in the seventh or eighth aspects of this article, can be used to treat patients who have developed renal fibrosis associated with the presence of short telomeres or are at risk of developing renal fibrosis associated with the presence of short telomeres. In one embodiment of the screening method, the situation of the non-human animal model of the second aspect or any embodiment thereof is compared and evaluated with the situation of wild-type mice or the situation of the non-human animal of the second aspect that is not treated with the test compound.

[0121] In the ninth aspect, the present invention relates to the use of a non-human animal model defined in the second aspect or any embodiment thereof in a screening method for a test compound for renal fibrosis associated with the presence of short telomeres. In a preferred embodiment, the method comprises the following steps:

[0122] i) administering a compound to a non-human animal model of renal fibrosis associated with the presence of short telomeres as defined in the second aspect or any embodiment thereof, ii) detecting or evaluating symptoms of renal fibrosis, and

[0123] iii) comparing the symptoms of renal fibrosis with those of an animal group not administered with the compound, and selecting a compound that improves the symptoms, and / or

[0124] iv) comparing the symptoms of renal fibrosis before and after administration of the test compound and selecting a compound that improves the symptoms.

[0125] It is noteworthy that the embodiments and definitions included in the second aspect of the present invention are also applicable to the third, fourth, fifth, sixth, seventh, eighth and ninth aspects.

[0126] Sequence Listing

[0127] SEQ ID NO:1

[0128]

[0129]

[0130]

[0131]

[0132] SEQ ID NO:2

[0133] MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSC

[0134] LKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHL

[0135] LARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSA

[0136] SRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHH

[0137] AGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLP

[0138] RLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHS

[0139] SPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAA

[0140] EHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQ

[0141] HREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLD

[0142] DIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFK

[0143] SHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSI

[0144] LSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDE

[0145] ALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLD

[0146] LQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGP

[0147] LPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD

[0148] SEQ ID NO:3

[0149]

[0150]

[0151]

[0152] SEQ ID NO:4

[0153] MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSC

[0154] LKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHL

[0155] LARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSA

[0156] SRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHH

[0157] AGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLP

[0158] RLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHS

[0159] SPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAA

[0160] EHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQ

[0161] HREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLD

[0162] DIHRAWRTFVLRVRAQDPPPELYFVKDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPY

[0163] MRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGD

[0164] MENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPA

[0165] HGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTN

[0166] <h2 style=";text-align:left;direction:ltr">IYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQ<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0167] <h2 style=";text-align:left;direction:ltr"> AFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0168] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:5<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0169] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0170] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0171] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0172] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:6 Acta2 F ATCACCAACTGGGACGACAT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0173] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:7 Acta2 R AGTGTCGGATGCTCTTCAGG<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0174] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:8 Vim F CATGATGCTTTGGGTAAAATGG<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0175] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:9 Vim R AGTGGGTGTCAACCAGAGGA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0176] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:10 Col1a1 F TGGAATCATGGTATTTGGAACA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0177] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:11 Col1a1 R TAGTCGTATGCTGCCTTGGG<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0178] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:12 Col1a2 F CAGGGCCTGATGGAAAACAA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0179] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:13 Col1a2 R ACCCCTCTCTCCTGGAAGC<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0180] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:14 Col3a1 F ATAATGGGGAACGTGGTCCT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0181] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:15 Col3a1 R TGACCATCTGATCCAGGGTT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0182] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:16 Col4a1 F GTCTGGCTTCTGCTGCCTCTTC<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0183] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:17 Col4a1 R TCACATTTTCCACAGCCAGA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0184] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:18 Fn1 F CCTGGGAGAAGTTTGTGCAT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0185] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:19 Fn1 R ACTTGGACAGGTCCAGTTGTG<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0186] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:20 Emr1 F GCACCATCTTGCTGGAGACT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0187] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:21 Emr1 R TTCATTGATGACTTTGCTTTCG<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0188] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:22 Tgfb1 F GGAGAGCCCTGGATACCAAC<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0189] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:23 Tgfb1 R ATCCACTTCCAACCCAGGTC<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0190] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:24 Snai1 F ACCCTGCTGGTATCTCTCCC<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0191] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:25 Snai1 R TCTTCACATCCGAGTGGGTT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0192] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:26 Snai2 F GGCTGCTTCAAGGACACATT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0193] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:27 Snai2 R GTGCCCTCAGGTTTGATCTG<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0194] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:28 Zeb1 F CCAAGAACTGCTGGCAAGA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0195] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:29 Zeb1 R TTCGGATCATGGTTTTGCTC<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0196] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:30 Zeb2 F AAACAAGCCAATCCCAGGAG<h2 style=";text-align:left;direction:ltr">

[0197] SEQ ID NO:31 Zeb2 R GAGGGTTTGCAAGGCTATCA

[0198] SEQ ID NO:32 Twist F CACGCTGCCCTCGGACAA

[0199] SEQ ID NO:33 Twist R GGGACGCGGACATGGACC

[0200] SEQ ID NO:34 Kim-1 F CTCTACCTCCACTCCTCCAACA

[0201] SEQ ID NO:35 Kim-1 R CTCCTGAGGATGTCACAGTGC

[0202] SEQ ID NO:36 NGAL F CAATGTCACCTCCATCCTGG

[0203] SEQ ID NO:37 NGAL R CCTGGAGCTTGGAACAAATG

[0204] SEQ ID NO:38 Smad3 F TGAACACCAAGTGCATTACCA

[0205] SEQ ID NO:39 Smad3 R AGGCGGCAGTAGATAACGTG

[0206] SEQ ID NO:40 Cdh1 F GCAGAACTGTCCCTGTCCCAG

[0207] SEQ ID NO:41 Cdh1 R GAACAGCACGTACACAGCCCT

[0208] SEQ ID NO:42 Loxl2 F CCTACAACCCCAAAGCCTATAA

[0209] SEQ ID NO:43 Loxl2 R CGTGCAGTTCATAGAAAACTTCC

[0210] SEQ ID NO:44 GAPDH F AGGTCGGTGTGAACGGATTTG

[0211] SEQ ID NO:45 GAPDH R TGTAGACCATGTAGTTGAGGTCA

[0212] SEQ ID NO:46 Trf1 F TGGAAAATGAGAAAGCGAGG

[0213] SEQ ID NO:47 Trf1 R TTTCTGTAGACTGCTGGCATT

[0214] SEQ ID NO:48 mTERT F GGTGACAGATGCCTTGAACAC

[0215] SEQ ID NO:49 mTERT RGATCCTCTCCCTCAGACGGT

[0216] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, these descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entirety.

[0217] Example

[0218] Example 1: Method

[0219] Mice and animal procedures

[0220] Tert heterozygous mice were generated as previously described. 63 Backcrossed to >98% C57BL / 6 background. + / - Mice were crossed to produce the first generation (G1) homozygous Tert - / - Knockout mice. G3 Tert - / - Mice were generated by serial breeding of G2 Tert - / - Tert mice were generated from a pure C57BL / 6 background + / + and G3Tert - / - Male and female mice were treated with FA (F7876; Sigma-Aldrich). - / - Mice (7, 27, and 47 weeks of age) were euthanized to analyze the renal phenotype for signs of fibrosis and for RNA-seq analysis.

[0221] Trf1 lox / lox Mouse 64 Tamoxifen-inducible ubiquitin C (UBC) promoter 65 Crossbreeding of mice with CreERT2-driven recombinase to generate Trf1 lox / lox ;hUBC-CreERT2 or Trf1 + / +; hUBC-CreERT2 mice. Starting at 10 weeks of age, these mice began to eat freely a diet containing long-term tamoxifen.

[0222] All mice were produced and maintained in the Spanish National Cancer Research Center (CNIO) animal facility under specific pathogen-free conditions with a 12-h light / dark cycle. Mice were housed in plastic cages with sawdust or shredded wood bedding in accordance with the recommendations of the Federation of European Laboratory Animal Science Associations, with food and water available ad libitum. All animal procedures were approved by the CNIO-ISCIII Research and Animal Welfare Ethics Committee (CBA03_2019-v2).

[0223] Folic acid titration and vaccination

[0224] For 6 to 8 weeks old Tert + / + and G3 Tert - / - Mice were given a single intraperitoneal injection of 0.3 mmol l -1 NaHCO3) in different doses (50, 100, 125 and 250 mg kg -1 Body weight) of FA or vehicle alone. Blood was collected on days 7 and 14 and analyzed using the VetScan comprehensive diagnostic profile kit. Mice were euthanized on day 14 after FA injection, and kidneys were collected from FA-treated or vehicle-treated animals and analyzed for renal fibrosis by immunohistochemistry.

[0225] For 6 to 8 weeks old Tert + / + and G3 Tert - / - Mice were given a single intraperitoneal injection of 125 mg kg -1 Body weight low dose FA or 0.3M NaHCO3 (200ul). Blood was collected on days 2, 7 and 14 and analyzed using VetScan comprehensive diagnostic profile kit. Mice were euthanized on day 14, and kidneys were perfused with cold PBS and harvested.

[0226] Morphological analysis

[0227] Kidneys were fixed with 4% formaldehyde and embedded in paraffin. Paraffin sections (5 μm thick) were stained with Masson's trichrome, Sirius red, and PAS+D using standard procedures. The percentage of fibrotic area was quantified using the National Institutes of Health (NIH) ImageJ program.

[0228] Primary cell culture

[0229] Primary mouse PTCs were isolated from 10- to 11-week-old Tert + / + and G3 Tert - / - Mice, as previously described 66 mTert-pBabe-puro was a gift from M. Alvarez and J. Bidwell (Addgene plasmid number 36413). The retroviral plasmid vector (mTert-pBabe-puro) and packaging plasmids (PLC Eco and pCMV-VSV-G) were co-transfected into the packaging cell line 293T. Viral supernatant was collected 48 hours later, centrifuged to remove cell debris, filtered through a 0.45 μm filter (Millipore), and used to infect Tert cells. + / + and G3 Tert - / - PTC isolated from mice were treated with 2 μg ml -1 Stable cell lines were selected with puromycin, and cells were collected for RNA extraction and immunofluorescence analysis.

[0230] Immunohistochemistry and immunofluorescence staining

[0231] Kidney tissues were fixed with 4% formaldehyde and embedded in paraffin. Immunohistochemical staining was performed on paraffin-embedded kidney tissue sections with a thickness of 5-7 μm. The primary antibodies (and their dilutions) were: rat p21 monoclonal antibody (HUGO-291H / B5; CNIO Histopathology Core Unit; 1:400), rat p53 monoclonal antibody (POE316A / E9; CNIO Histopathology Core Unit; 1:400), rat p21 monoclonal antibody (HUGO-291H / B5; CNIO Histopathology Core Unit; 1:400), rat CD8a monoclonal antibody (AM-OTO94A; CNIO Histopathology Core Unit), mouse phospho-histone H2AX monoclonal antibody (Ser 139; 05-636; Millipore; 1:400), mouse E-cadherin monoclonal antibody (610182; BD Biosciences; 1:400), rat F4 / 80 monoclonal antibody (MCA497; AbD Serotec; 1:400), rabbit polyclonal activated caspase-3 (9661; Cell Signaling Technology; 1:400). Technology; 1:400), rabbit CD3e monoclonal antibody (99940; Cell Signaling Technology; 1:400), rabbit CD4 monoclonal antibody (25229; Cell Signaling Technology; 1:400), rabbit collagen VI polyclonal antibody (ab6588; Abcam; 1:400), rabbit fibronectin polyclonal antibody (ab2413; Abcam; 1:400), and rabbit Sox9 polyclonal antibody (AB5535; Millipore; 1:400).

[0232] For immunofluorescence, mouse α-SMA-Cy3 monoclonal antibody (C6198; Sigma; 1:400), rabbit vimentin monoclonal antibody (5741; Cell Signaling Technology; 1:200), rabbit Ki67 monoclonal antibody (12202; Cell Signaling Technology; 1:400), rabbit TGFβ polyclonal antibody (3711S; Cell Signaling Technology; 1:200), rabbit SNAIL+SLUG polyclonal antibody (ab180714; Abcam; 1:200), and rat E-cadherin monoclonal antibody (DECMA-1; ab11512, Abcam; 1:200) were used. Images were acquired using a confocal superspectral microscope (Leica TCS-SP5). The percentage of immunohistochemical and immunofluorescence positive staining areas was quantified using NIH ImageJ (v1.52n).

[0233] Gene expression analysis and real-time PCR detection

[0234] Total RNA was isolated from kidney tissue and PTC using TRIzol reagent (Takara) according to the manufacturer's instructions. cDNA was synthesized using 1 μg of total RNA, cDNA synthesis mix (BioMake), and oligo-dT primers. Gene expression was measured by real-time PCR detection (BioMake) and 7900HT Real-Time PCR System (Applied Biosystems). The relative amount of mRNA compared to the internal control was calculated as 2 ΔCT , where ΔCT = ΔCT experimental - ΔCT control The genes and primers are listed in Table 2 (F: forward primer; R: reverse primer).

[0235] Table 2: qPCR primers used in this study (sequence (5'-3'))

[0236]

[0237]

[0238] For RNA-seq experiments, total RNA samples (300 ng) were used. The RNA quality score averaged 6.3 (range 4.7–8.0) when tested using a PerkinElmer LabChip analyzer. Sequencing libraries were prepared using the QuantSeq 3′mRNA-Seq Library Preparation Kit for Illumina (FWD) (Lexogen; 015) following the manufacturer’s instructions. Library generation was initiated by oligo-dT-primed reverse transcription, and second-strand synthesis was performed by DNA polymerase from random primers. Primers in both steps contained sequences compatible with Illumina. cDNA libraries were purified, applied to an Illumina flow cell for cluster generation, and sequenced on an Illumina NextSeq 550 (with v2.5 kit) following the manufacturer’s protocol. Read adapters and poly(A) tails were removed using the command “bbduk.sh” as recommended by Lexogen. Sequencing was performed using the Nextpresso pipeline. 67 The processed reads were analyzed as follows. FastQC v0.11.7 ( https: / / www.bioinformatics.b abraham.ac.uk / projects / fastqc / ) to check the sequencing quality. Bowtie (v1.0.0) was used 69 and SAMtools (v0.1.19) 70(--library-type fr-secondstrand in TopHat) Use TopHat (v2.0.10) 68 Reads were aligned to the mouse reference genome (GRCm38) allowing 3 mismatches and 20 multiple matches. Mouse gene annotations from GENCODE (GRCm38; vM20Ensembl 95) were used and the results were obtained by HTSeq-count (v0.6.1). 71 Get read counts. GSEAPreranked 72 For performing GSEA on several gene signatures on a pre-ranked gene list, 1,000 gene set permutations were set. Only gene sets with significant enrichment levels (FDR q-value < 0.25) were considered.

[0239] Telomere analysis

[0240] Q-FISH assays were performed on paraffin-embedded tissue sections as previously described. 41 . After dewaxing, the tissues were fixed in 4% formaldehyde for 5 min, washed three times in PBS for 5 min each, and then incubated in a pepsin solution (0.1% porcine pepsin, Sigma; 0.01 M HCl, Merck) for 15 min at 37°C. After another round of washing and fixation as above, the slides were dehydrated in an ethanol series (70%, 90%, and 100%; 5 min each). After air drying for 10 min, 30 l of telomere probe mix (10 mM Tris-Cl (pH 7), 25 mM MgCl2, 9 mM citric acid, 82 mM Na2HPO4, 70% deionized formamide (Sigma), 0.25% blocking reagent (Roche), and 0.5 μg ml -1 Telomere PNA probes (Panagene) were added to each slide. Coverslips were added and slides were incubated at 85°C for 3 min and then incubated for another 2 h at room temperature in a dark humidified chamber. Slides were washed twice with vigorous shaking in 10 mM Tris-Cl (pH 7), 0.1% BSA in 70% formamide for 15 min each, then washed three times in 0.08% TBS containing Tween 20 for 5 min each, and then incubated in a DAPI bath (4 μg ml in PBS). -1 ; Sigma), and then the samples were mounted in Vectashield medium (Vector). A Leica SP5-MP confocal microscope was used to acquire confocal images every 1 μm, for a total of 5 μm, and the maximum projection was completed using LAS-AF software. Definiens software was used to quantify telomere signal intensity.

[0241] Statistics and reproducibility

[0242] No statistical methods were used to predetermine sample size, but our sample size was similar to those reported previously 4 , 46 Mice were randomly assigned to groups, and investigators were blinded to group assignment. Our sample sizes corresponded to the number of mice used in each experiment, as indicated. Quantitative analysis of immunohistochemical staining was performed on whole scanned kidney sections containing 10–15 fields. For immunofluorescence analysis, we collected 10–20 images from each individual. Data distribution was assumed to be normal but was not formally tested. No data points or mice were excluded from the analysis. Statistical analysis Results are presented as mean ± sem. Statistical analysis was performed using one-way ANOVA with post hoc Tukey's test in Prism (GraphPad) for quantification of immunohistochemistry / immunofluorescence and qPCR and Q-FISH analysis. Two-way ANOVA with post hoc Bonferroni test was used to analyze blood and urine parameters. Statistical significance was defined as P < 0.05.

[0243] Example 2: Results

[0244] Mouse model of renal fibrosis linked to short telomeres

[0245] To test the role of short telomeres in renal fibrosis, we first analyzed kidneys from wild-type mice, as well as mice lacking the catalytic subunit of telomerase, Tert, which had been bred for three generations (G3) to induce the presence of very short telomeres, i.e., G3 Tert - / - Mouse 24 (picture 9a ). 8-9 weeks old wild type (Tert + / + ) and G3 Tert - / - All mice showed grossly normal renal histology, with no evidence of glomerular or tubular defects and no fibrosis or collagen fiber accumulation, as determined by Masson's trichrome and Sirius red staining, respectively (Fig. 9b,c ). Similarly, we did not detect increased tubular damage or brush border loss in the kidneys, as determined by periodic acid-Schiff+diastase staining (PAS+D; Fig. 9d ). In addition, with G3 Tert - / - The grossly normal kidneys of mice are consistent with those of age-matched Tert + / +Compared with WT mice, we observed no differences in the presence of activated fibroblasts (determined by expression of smooth muscle actin (α-SMA)); apoptosis (determined by expression of cleaved caspase 3 (CC3)); senescence (determined by expression of the p21 cell cycle inhibitor); or expression of E-cadherin (an EMT marker associated with tissue fibrosis) (Fig. 9e–h ).

[0246] The incidence of renal fibrosis increases with age; therefore, it may result from a combination of molecular and cellular aging events, such as the presence of short telomeres. 14 Therefore, we next attacked Tert with FA + / + and G3 Tert - / - Mouse kidney, previously described at 250 mg kg -1 High doses of body weight induce renal fibrosis 27 FA-induced nephropathy is widely used to study interstitial renal fibrosis. 4 , 27 , 28 In particular, intraperitoneal injection of FA into mice resulted in the rapid appearance of FA crystals in the renal tubules, leading to severe nephrotoxicity.

[0247] To do this, we first let 8-9 week old Tert + / + and G3 Tert - / - Mice received increasing doses of FA (50, 100, 125, and 250 mg kg -1 Weight; Figure 1a ), and the highest FA dose that did not induce renal fibrosis in wild-type mice was selected. -1 The wild-type mice treated with WT did well and did not show any signs of renal pathology as evidenced by the normal kidney appearance ( Figure 1 b) The creatinine and blood urea nitrogen (BUN) in the blood were normal (Fig. 1c,d ) and the absence of fibrosis indicated by Masson’s trichrome staining (Fig. 1e ) and the absence of tubular damage indicated by PAS+D staining (Fig. 1e ) was determined. In contrast, patients receiving 250 mg kg -1 Most wild-type mice (75%) treated with FA at a dose of 125 mg kg body weight died of FA-induced acute renal failure on day 2 after treatment (data not shown). -1 is the maximum tolerated dose of FA that does not cause death in wild-type mice with normal telomere length. We infer that although this dose of FA is insufficient to induce Tert + / +mice, but may synergize with the short telomeres of telomerase-deficient mice to induce renal fibrosis.

[0248] In fact, we used the same dose of FA to treat G3 Tert - / - Mice were treated and it was observed that even at 125 mg / kg -1 After the dose, the kidneys still appear pale ( Figure 1 b), suggesting the presence of renal fibrosis. In fact, G3 Tert treated with increasing doses of FA - / - Mice showed that at 125 mg kg -1 At the FA dose, the creatinine in the blood (Fig. 1c ) and BUN (Fig. 1d ) levels, indicating the presence of renal failure, and increased fibrosis as detected by Masson's trichrome staining (Fig. 1e ) and increased tubular damage as determined by increased PAS+D staining (Fig. 1e ). Less than 125mg kg -1 The FA dose will not be in G3 Tert - / - Induced fibrotic phenotype in mice (Fig. 1e ). Therefore, we choose 125 mg kg -1 The FA doses based on body weight were used for further experiments.

[0249] Treatment of telomerase-deficient mice with sublethal doses of folic acid results in severe renal dysfunction

[0250] To investigate the role of short telomeres in renal fibrosis, we gave 8-9 week old Tert + / + and G3 Tert - / - Mice were injected with 125 mg kg -1 body weight dose of FA, which does not induce fibrosis in wild-type mice (Fig. 2a ). Blood was collected from the submandibular vein on days 2, 7, and 14. On day 14, mice were euthanized and kidneys were removed for further analysis. As expected, G3 Tert kidneys treated with FA showed increased expression of FA compared to similarly treated wild-type kidneys. - / - The mice's kidneys appeared pale and damaged (Figure 2b,c To confirm kidney damage, we analyzed urine parameters and observed a significant difference in FA-treated Tert + / + and unprocessed Tert + / + Mouse and G3 Tert - / - Compared with mice treated with FA, G3 Tert - / - The 24-hour urinary albumin excretion and urinary albumin to creatinine ratio of mice were significantly increased (Fig. 2b ).

[0251] We also examined BUN and creatinine in all mouse groups. High-dose FA is known to cause transient increases in BUN and creatinine levels 48 hours after injection, followed by renal dysfunction and interstitial fibrosis. 29 However, injection of low-dose FA (125 mg kg -1 Body weight) Two days later, untreated and FA-treated wild-type mice (Tert + / + ) showed normal BUN and creatinine levels, indicating normal renal function (Fig. 10a,b Consistently, we did not observe any significant differences in the expression of FA with low doses (125 mg kg -1 Body weight) treated wild-type mice (Tert + / + ) decreased activity or increased mortality. Similarly, untreated G3 Tert - / - Mice showed normal creatinine and BUN levels and normal vitality on day 2. As expected, FA-treated G3Tert - / - The BUN and creatinine levels of mice increased significantly on days 2, 7, and 14, and the creatinine level gradually increased after day 2, indicating that renal dysfunction occurred as early as 2 days after FA administration (Fig. 10a,b ). + / + and G3 Tert - / - Other biochemical parameters in the blood of mice indicated kidney damage (Table 1 ). Alkaline phosphatase and amylase levels are often elevated in patients with CKD and those requiring dialysis. 30 , which is an indication of kidney damage 31 Impaired renal function may lead to hyperamylasemia 32 On days 7 and 14, G3 Tert- / - mice had significantly higher levels of alkaline phosphatase and amylase than those treated with FA + / + And unprocessed Tert + / + Mouse and G3 Tert- / - mouse levels (Table 1 ). Hypercalcemia 33 , hyperphosphatemia 34 , hypernatremia 35 and hyperkalemia 36 is a common complication in CKD patients, especially those with end-stage renal disease. + / + And unprocessed Tert + / + Mouse and G3Tert- / - mice treated with FA compared to G3Tert- / - The calcium, phosphorus, and sodium levels of mice increased on days 2, 7, and 14, whereas the potassium level increased only on day 14 (Table 1 As indicators of tubular function, we measured blood glucose, globulin, total protein, and albumin levels. + / + and unprocessed Tert + / + Mouse and G3 Tert- / - mice treated with FA compared to G3 Tert- / - mice showed significant increases in blood glucose, globulin, and total protein levels, whereas albumin remained unchanged (Table 1 ).

[0252] Table 1: Blood parameters of mice on days 2, 7 and 14 after FA. Data are presented as mean ± SD of the mean.

[0253]

[0254] a p<0.001vs.Tert + / + , b p<0.001 vs. FA-treated Tert + / + , c p<0.001vs.G3Tert - / -

[0255] d p<0.01vs.Tert + / + , e p<0.01 vs. FA-treated Tert + / + , f p<0.01vs.G3Tert - / -

[0256] g p<0.05vs.Tert + / + ; h p<0.05 vs. FA-treated Tert + / + , p<0.05vs.G3Tert - / -

[0257] Telomerase-deficient mice develop collagen deposition and activated myogenesis in the kidneys after sublethal administration of folic acid Fibroblasts

[0258] It has been previously shown that FA-induced renal injury is associated with segmental interstitial fibrotic lesions that appear approximately 2 weeks after treatment. 37 Consistent with this, we observed that FA-treated G3 Tert - / -There were interstitial fibrosis areas in the mouse kidneys indicated by Masson's trichrome staining and Sirius red staining, and in G3 Tert - / - ,Tert + / + and FA-treated Tert + / + No fibrosis was detected in the kidneys of mice (Fig. 2c ), again suggesting that short telomeres are susceptible to renal fibrosis after administration of sublethal doses of FA that do not induce fibrosis in wild-type mice. + / + and unprocessed Tert + / + Mouse and G3 Tert - / - Compared with normal kidney histology of FA-treated G3 Tert mice - / - The mice also developed significant tubulointerstitial damage, as evidenced by increased PAS+D staining, including tubular dilation, atrophy, and loss of epithelial differentiation following injury (Fig. 2c Next, we performed immunohistochemistry for α-SMA, fibronectin, and type VI collagen, and double immunofluorescence for α-SMA and vimentin to detect interstitial myofibroblasts (Fig. 3a ). Similarly, Tert treated with FA + / + and unprocessed Tert + / + Mouse and G3 Tert - / - In contrast, no staining was detected in either mouse model, we detected only G3 Tert in the FA-treated - / - The staining of α-SMA, fibronectin, type VI collagen, and vimentin was increased in mice (Fig. 3a ).

[0259] EMT involves a shift from the apical-basolateral polarity of epithelial cells to the anterior-posterior polarity of mesenchymal cells, as well as the expression of mesenchymal markers such as fibroblast-specific protein 1, vimentin, N-cadherin, and α-SMA. These changes induce enhanced migration ability, invasiveness, increased resistance to apoptosis, and increased production of ECM components. 38 To demonstrate that G3 Tert treated with FA - / - We found that the proliferating cells observed in the mice were indeed EMT cells rather than tubular cells, and we performed double immunofluorescence staining for Ki67 and α-SMA. - / - Compared with mice treated with FA, G3 Tert - / - 36% of proliferating cells in mice are myofibroblasts (α-SMA + Ki67 + )(picture 3bQuantitative PCR (qPCR) to determine the mRNA levels of key fibrotic genes including Acta2 (encoding α-SMA) and Vim (encoding vimentin), Col1a1, Col3a1, and Col4a1 (encoding type I collagen α-1, α-3, and α-4 chains, respectively), and Fn1 (encoding fibronectin 1) also confirmed that FA-treated G3 Tert - / - Fibrosis was increased in FA-treated Tert mice, whereas fibrosis was not increased in similarly treated wild-type or untreated mice. + / + and unprocessed Tert + / + Mouse and G3 Tert - / - Compared with mice treated with FA, G3 Tert - / - These genes were significantly upregulated in the kidneys of mice (Fig. 3c ).

[0260] Sublethal folic acid administration increases renal apoptosis and senescence in telomerase-deficient mice

[0261] We and others have shown that short telomeres induce a persistent DNA damage response at chromosome ends, leading to cell cycle arrest or apoptosis. 39 , 40 In particular, short telomeres induce the p53 and p21 cell cycle inhibitors 22 , 41 Interestingly, p21 is an activator of TGFβ 37 , thus providing a potential mechanism by which short telomeres may contribute to the activation of the EMT program even in the absence of fibrosis.

[0262] In this regard, we investigated G3 Tert treated with FA - / - Whether the renal dysfunction and increased fibrosis in mice are accompanied by increased cellular senescence or apoptosis, two well-known cellular responses to telomere dysfunction during aging 14 We observed that FA treatment resulted in G3Tert - / - The levels of CC3 (a marker of apoptosis), p21 and p53 cell cycle inhibitors, and γ-H2AX (a marker of DNA damage) were significantly increased in FA-treated Tert mice. + / + and unprocessed Tert + / + Mouse and G3 Tert - / - Levels in mice were undetectable (Fig. 4a–d ). Our model suggests that these events lead to increased renal cell turnover, which in turn results in telomere shortening. In support of this, we observed increased transcript levels of genes encoding cell cycle regulators CCnd1, Ccnd2, Ccnb1, and Ccne1 (Fig. 11a), suggesting a pronounced profibrotic phenotype leading to G2 / M arrest. Finally, we identified G3 Tert by performing telomere quantitative fluorescence in situ hybridization (Q-FISH) directly on kidney sections. - / - The telomeres in the kidneys of mice were shorter than those in wild-type mice (Fig. 4e Low-dose FA treatment resulted in significant shortening of telomeres in both genotypes (Fig. 4e ).

[0263] Short telomeres promote tubular damage and immune infiltration in the kidney

[0264] Next, we investigated the pathways by which short telomeres induce renal damage. Kidney injury molecule-1 (KIM-1, also known as hepatitis A virus cellular receptor (HAVCR) 1; encoded by the gene Havcr1) is a type 1 transmembrane protein that is undetectable in healthy kidneys but is induced in large amounts following injury. 42 , localized on the apical surface of surviving proximal tubule cells (PTCs) 43 Inflammation is considered a major driver of renal fibrosis 42 , Neutrophil gelatinase-associated lipocalin (NGAL) gene product (lipocalin-2 (Lcn2) or ferrocalin) 44 In acute kidney injury (AKI) 44 Therefore, we used Havcr1 and Lnc2 as biomarkers of CKD caused by tubulointerstitial damage. We found that Tert + / + and control, untreated Tert + / + Mouse and G3 Tert - / - Compared with the basal expression of G3Tert in FA-treated mice - / - Havcr1 and Lnc2 in mice were upregulated by 134 and 206 times, respectively (Fig. 5a Next, we investigated the expression of molecules involved in immune infiltration, which is also associated with tissue fibrosis. We observed that FA-treated G3 Tert - / - The expression of Emr1 mRNA in mice (the mouse gene encoding the F4 / 80 antigen) was upregulated by 16-fold (Fig. 5a We also examined the expression of pan-macrophage marker F4 / 80 and T cell markers (CD3e, CD4, and CD8a) by immunohistochemistry. We observed that FA-treated Tert + / + Mice or untreated Tert + / + and G3 Tert - / - Compared with mice treated with FA, G3 Tert - / - Macrophage colonization (F4 / 80 positive area) and T cell increase in mouse kidneys (Fig.5b ).

[0265] G3 Tert - / - Activation of epithelial-mesenchymal transition-related pathways in mice

[0266] It is known that TGFβ is involved in the recruitment of macrophages in tissue fibrosis, which is relevant to renal fibrosis. 46 Related EMT processes 45 Therefore, we next sought to determine whether the presence of short telomeres was associated with changes in the expression of EMT-related genes. To this end, we performed a double-blind experiment on untreated or low-dose FA (125 mg kg -1 Body weight) of 10-week-old Tert + / + and G3Tert - / - The kidneys of mice were subjected to RNA sequencing (RNA-seq) to investigate the expression of EMT and EMT-related pathways such as TGFβ signaling, which is the main environmental stimulus that induces EMT in adult epithelial cells. + / + Compared with untreated G3Tert - / - Gene set enrichment analysis (GSEA) of mice showed that EMT (normalized enrichment score (NES) = 3.37) and TGFβ (NES = 1.9) pathways were upregulated in telomerase-deficient mice compared with wild-type mice (Fig. 6a,b ), suggesting that short telomeres may lead to a higher basal activation of some EMT genes. + / + Animals and G3 Tert treated with FA - / - Transcriptional upregulation of EMT genes was more pronounced in untreated 7-week-old Tert + / + Compared with G3 Tert mice - / - mice, and older mice (47 weeks old; Fig. 12a,b ). Thus, short telomeres are associated with changes in the expression levels of some, but not all, genes involved in EMT in renal epithelial cells and are therefore insufficient to activate the classical EMT program or induce fibrosis on their own. Interestingly, FA treatment induced the expression of Tert + / + and G3 Tert - / - Enrichment of EMT and TGFβ pathways in both genotypes. + / + Compared with kidneys treated with FA, G3 Tert - / - This enrichment was higher in the kidney (NES = 2.42), supporting the notion that telomerase-deficient mice have a higher degree of EMT activation in response to FA (Fig. 6a,b ).

[0267] Key EMT transcription factors are upregulated in telomerase-deficient mice with short telomeres

[0268] TGFβ1-induced EMT is mediated by ZEB1 and SNAIL in a Smad-dependent manner 45 TWIST, SNAIL, and ZEB1 are transcription factors that regulate the EMT transcriptional program. Activation of Twist, Snail, or Zeb1 is sufficient to induce a mesenchymal phenotype 4 Therefore, we performed reverse transcription-PCR (RT-PCR) to determine the mRNA expression levels of Tgfb1, Snail1, Snail2, Twist1, Zeb1, and Zeb2. We observed that FA-treated G3 Tert - / - The expression of Tgfb1 in mice was enhanced by 32 times (Fig. 6c ). In FA-treated G3 Tert - / - In mice, Snail1 and Snail2 were also upregulated sixfold (Fig. 6c ). In FA-treated G3 Tert - / - In mice, Twist1 was upregulated sevenfold, while Zeb1 and Zeb2 were upregulated fourfold and fivefold, respectively (Fig. 6c ). Thus, in the kidneys of telomerase-deficient mice with short telomeres that received sublethal doses of FA, all major EMT players were upregulated compared to wild-type mice that received the same dose of FA, suggesting that short telomeres can lead to EMT changes after FA treatment. Lysyl oxidase (LOXL2) is necessary and sufficient for hypoxic inhibition of E-cadherin, which mediates cellular transformation and induces EMT 47 . G3 Tert treated with FA - / - In mice, the expression of Loxl2 was upregulated 20-fold (Fig. 6c One of the hallmarks of EMT is the downregulation of E-cadherin isoforms such as Cdh1 and the expression of mesenchymal markers. 45 Consistent with this, FA-treated G3 Tert - / - The expression of E-cadherin Cdh1 in mice was downregulated to 1 / 2, as confirmed by mRNA levels and immunohistochemistry (Fig. 6c,d SMAD3 is a key effector in TGFβ signaling. We found that in FA-treated G3 Tert - / - Smad3 was upregulated twofold in mice (Fig. 6c,d ).

[0269] To understand how short telomeres affect progenitor and stem cells during FA-induced renal fibrosis, we investigated the expression of sex-determining region Y box 9 (Sox9), Wilms tumor (Wt1), paired box 2 (Pax2), spalt-like transcription factor 2 (Sall2), activin A receptor type 2B (Acvr2b, a member of the Tgfb superfamily), and Klotho (Kl). 48 Kazuto 49 Research shows that SOX9 plays an important role in kidney development and is a key regulator of renal fibrosis 50 This precedes the expression of Wt1, Pax2, and NOTCH signaling in epithelial cells. Wt1 maintains the transition between mesenchymal and epithelial cell states, is required for the induction of mesenchymal-epithelial transition (MET), and plays a key role in the progression of nephrogenesis 51 The nuclear transcription factor PAX2 is associated with MET and is required for renal cell differentiation 52 Re-expression of Wt1 and Pax2 in renal tubular epithelial cells plays an important role in promoting EMT, and silencing Pax2 and Wt1 may have therapeutic value to prevent or reverse renal fibrosis 53 In this regard, we observed that Tert exposed to FA had a - / - Transcript levels of Sox9, Pax2, Wt1, and Acvr2b expression in mice were significantly increased, suggesting that under these conditions, short telomeres sensitize the kidneys to undergo EMT (Figure ​Figure3). 13a ). Compared with untreated and treated Tert + / + Mouse and G3 Tert - / - Compared with mice treated with FA, G3 Tert - / - Sox9 immunostaining in mice was significantly increased (Fig. 13b ). Sall2 is negatively regulated by Wt1 (ref. 54 ), Klotho (Kl) is an anti-aging protein produced mainly in the kidney 55 , which regulates telomerase activity 56 Low Kl levels may be a pathological intermediate that exacerbates renal damage. Interestingly, we found that in FA-treated G3 Tert - / - The expression of Sall2 and Kl was downregulated in mice (Fig. 13a ).

[0270] Sustained expression of NOTCH signaling pathway in epithelium leads to interstitial fibrosis 57 NOTCH is a strong regulator of SNAIL1 and SNAIL2 (ref. 58 ). Therefore, we analyzed the direct Notch targets that are important for renal function.59 We found that FA-treated Tert + / + And unprocessed Tert + / + Mouse and G3 Tert - / - Compared with mice treated with FA, G3 Tert - / - The Notch1 and Notch2 of mice increased threefold, and Notch3 and Jag1 increased fourfold (Fig. 14 We also found that Tert treated with FA + / + And unprocessed Tert + / + Mouse and G3 Tert - / - Compared with mice treated with FA, G3 Tert - / - Tfam in mice was upregulated fivefold (Fig. 14 ).

[0271] Telomere dysfunction induced by Trf1 loss triggers renal fibrosis associated with EMT activation

[0272] To evaluate the contribution of dysfunctional telomeres to the induction of renal fibrosis, we used a second model in which telomere dysfunction is induced by the deletion of TRF1, a component of the telomere protection complex. Specifically, we used our previously described mouse model 60 , where treatment with tamoxifen resulted in the loss of Trf1 in all renal cells (Fig. 7 The tamoxifen diet was maintained until humane endpoint, and Trf1 deficiency was confirmed by RT-qPCR (Fig. 7a Trf1-deficient mice developed renal fibrosis, which was similar to Trf1 + / + Compared with mice, the collagen deposition was increased (Masson's trichrome staining) and fibrotic lesions (Sirius red staining) (Fig. 7b ), and myofibroblasts were activated (SMA staining; Fig. 7b We also observed that + / + Compared with mice, Trf1 flox / flox The mesenchymal markers (Acta2 and Fn1) of mice increased by three to four times, and the EMT markers (Tgfb1, Snail1, Snail2, Twist1, Zeb1, and Zeb2) increased by two to six times (Fig. 7c,d ), suggesting that dysfunctional telomeres may also contribute to transcriptional changes associated with EMT.

[0273] Telomerase overexpression rescues EMT changes associated with short telomeres

[0274] To further explore the contribution of short telomeres in the activation of the renal EMT program, we investigated whether they could be rescued by expressing the catalytic subunit of telomerase or TERT 61 To do this, we first started with 10- to 11-week-old Tert + / + and G3Tert - / - Renal epithelial cells, specifically PTCs, were isolated from mice. PTCs were transduced with either an empty vector or a vector expressing Tert ( Methods Telomerase overexpression was confirmed by qPCR (Fig. 8a ). Consistent with telomerase overexpression, wild-type and G3 Tert - / - After 1 week of culture, the cells showed a significant increase in telomere length (Fig. 8b ). Before transduction, on day 8 of culture, G3Tert - / - The cells exhibited a clear mesenchymal morphology, showing a spindle-like shape, which was not observed in wild-type cells that exhibited a cobblestone-like morphology (Fig. 15a ). G3 Tert transduced with empty vector - / - The cells displayed a complete myofibroblast phenotype, characterized by loss of E-cadherin, enhanced SMA staining, and positivity for Snail1 and TGFβ markers (Fig. 8c and Figure 15b,c ), indicating that 100% of cells underwent EMT. + / + The cells showed epithelial cells (E-cadherin-positive, Snail1- and TGFβ-negative, and SMA-negative cells) and myofibroblasts (E-cadherin-negative, Snail1- and TGFβ-positive, and SMA-positive cells; Fig. 8c and Figure 15b,c ), showing some evidence of EMT. + / + The cells exhibited phenotypic reversion, including evidence of MET, restoration of the cobblestone phenotype in culture, expression of E-cadherin, and loss of SMA, TGFβ, and Snail1 expression (Fig. 8c,d and Figure 15b,c Importantly, G3 Tert transduced with mTERT - / - The cells also showed a reversion to a mesenchymal phenotype with loss of SMA, TGFβ, and Snail1 expression (Fig. 8c and Figure 15b,c ). In fact, compared with G3Tert transduced with empty vector - / - Compared with G3 Tert cells transduced with mTERT - / -The expression of many ECM (Acta2, Vim, Col3a1, and Col4a1) and EMT (Tgfb1, Snail1, Snail2, and Zeb1) genes in the cells was decreased (Fig. 8d ), confirmed the restoration of epithelial characteristics after TERT expression and telomere lengthening. Therefore, our results indicate that mTERT overexpression and telomere lengthening are sufficient to rescue the EMT phenotype and restore the MET phenotype in renal tubular cells. This culture system provides a powerful tool for studying TERT-driven EMT.

[0275] Example 3: Discussion

[0276] EMT is a process of cellular plasticity by which the epithelium loses its integrity with a concomitant loss of cell polarity and cell-cell interactions mediated by the loss of E-cadherin 3 The resulting cells exhibit mesenchymal properties, including the expression of vimentin and α-SMA. EMT is regulated by multiple transcription factors (EMT-TFs) and is involved in normal development. 3 and pathological conditions such as cancer and various tissue fibrotic diseases (including renal fibrosis) 4 , 62 All play a key role.

[0277] Since both cancer and tissue fibrosis are associated with aging, understanding the known molecular and cellular mechanisms of aging is important. 14 How it may affect the expression of EMT-TF and the origin of the EMT pathological process is particularly important.

[0278] The accumulation of short and dysfunctional telomeres associated with cell division during the life cycle of an organism is considered one of the main hallmarks of aging, as it triggers persistent DNA damage that is sufficient to impair the regenerative capacity of the adult stem cell compartment. 10 , 13 In fact, mice 24 , 25 Kazuto 8 Telomerase deficiency leads to accelerated telomere shortening, which can lead to premature loss of tissue regeneration capacity, including the development of tissue fibrosis, of which pulmonary fibrosis is the most common. 8 , 22 .

[0279] Here, we generated a mouse model of renal fibrosis associated with short telomeres by challenging telomerase-deficient mice with short telomeres with a low sublethal dose of FA, an agent that is harmful to the kidneys, while this dose of FA does not induce fibrosis in similarly treated wild-type controls. Telomerase-deficient mice treated with sublethal doses of FA display all the hallmarks of the human disease, including severe renal dysfunction as evidenced by elevated levels of creatinine and urea in the blood. Furthermore, mice with telomere dysfunction due to the loss of Trf1, which encodes a telomere protein complex, spontaneously develop renal fibrosis, underscoring the importance of proper telomere function in preventing fibrotic pathology. Thus, the new mouse model generated here is an excellent tool to understand the role of short and dysfunctional telomeres and the resulting DNA damage in the molecular events associated with fibrosis.

[0280] Interestingly, we found that short telomeres induce changes in the expression of genes involved in EMT, although these changes were not sufficient to induce renal fibrosis. These changes were further exacerbated in telomerase-deficient mice treated with FA and developed renal fibrosis. This was supported by increased expression of the Snail1, Snail2, Zeb1, Zeb2, and Twist1 transcription factors, which lead to the transition of epithelial cells to myofibroblasts. Myofibroblasts deposit collagen-containing ECM, which leads to the development of renal fibrosis.

[0281] Supporting evidence that short telomeres induce EMT changes, we found that expression of the catalytic subunit of mouse telomerase TERT and subsequent telomere lengthening was sufficient to reverse the EMT program and restore the epithelial phenotype of kidney cells in culture.

[0282] References

[0283] 1. Luyckx, VA, Tonelli, M. & Stanifer, JW. The global burden of kidney disease and the sustainable development goals. Bull. World Health Organ. 96, 414–422C (2018).

[0284] 2. Humphreys, BDMechanisms of renal fibrosis. Annu. Rev. Physiol. 80, 309–326 (2018).

[0285] 3.Dongre,A.&Weinberg,R.A.New insights into the mechanisms ofepithelial–mesenchymal transition and implications forcancer.Nat.Rev.Mol.Cell Biol.20,69–84(2019).

[0286] 4.Grande,M.T.et al.Snail1-induced partial epithelial-to-mesenchymaltransition drives renal fibrosis in mice and can be targeted to reverseestablished disease.Nat.Med.21,989–997(2015).

[0287] 5.Inoue,T.,Okada,H.,Takenaka,T.,Watanabe,Y.&Suzuki,H.A case reportsuggesting the occurrence of epithelial–mesenchymal transition in obstructivenephropathy.Clin.Exp.Nephrol.13,385–388(2009).

[0288] 6.Martinez,P.&Blasco,M.A.Telomere-driven diseases and telomere-targeting therapies.J.Cell Biol.216,875–887(2017).

[0289] 7.de Lange,T.Shelterin-mediated telomereprotection.Annu.Rev.Genet.52,223–247(2018).

[0290] 8.Armanios,M.&Blackburn,E.H.The telomere syndromes.Nat.Rev.Genet.13,693–704(2012).

[0291] 9.Blackburn,E.H.Telomere states and cell fates.Nature 408,53–56(2000).

[0292] 10.Blasco,M.A.Telomeres and human disease:ageing,cancer andbeyond.Nat.Rev.Genet.6,611–622(2005).

[0293] 11.IJpma,A.S.&Greider,C.W.Short telomeres induce a DNA damageresponse in Saccharomycescerevisiae.Mol.Biol.Cell 14,987–1001(2003).

[0294] 12.Blasco,M.A.,Funk,W.,Villeponteau,B.&Greider,C.W.Functionalcharacterization and developmentalregulation of mouse telomerase RNA.Science269,1267–1270(1995).

[0295] 13.Flores,I.,Cayuela,M.L.&Blasco,M.A.Effects of telomerase andtelomere length on epidermal stemcell behavior.Science 309,1253–1256(2005).

[0296] 14.Lopez-Otin,C.,Blasco,M.A.,Partridge,L.,Serrano,M.&Kroemer,G.Thehallmarks of aging.Cell153,1194–1217(2013).

[0297] 15.Armanios,M.Y.et al.Telomerase mutations in families withidiopathic pulmonary fibrosis.N.Engl.J.Med.356,1317–1326(2007).

[0298] 16.Armanios,M.Telomerase mutations and the pulmonary fibrosis–bonemarrow failure syndrome complex.N.Engl.J.Med.367,384(2012).

[0299] 17.Mitchell,J.R.,Wood,E.&Collins,K.A telomerase component isdefective in the human diseasedyskeratosis congenita.Nature 402,551–555(1999).

[0300] 18.Tsakiri,K.D.et al.Adult-onset pulmonary fibrosis caused bymutations in telomerase.Proc.Natl Acad.Sci.USA104,7552–7557(2007).

[0301] 19.Coresh,J.,Astor,B.C.,Greene,T.,Eknoyan,G.&Levey,A.S.Prevalence ofchronic kidney disease anddecreased kidney function in the adult US

[0302] population:Third National Health and Nutrition ExaminationSurvey.Am.J.Kidney Dis.41,1–12(2003).

[0303] 20.Beier,F.,Foronda,M.,Martinez,P.&Blasco,M.A.Conditional TRF1knockout in the hematopoieticcompartment leads to bone marrow failure andrecapitulates clinical features of dyskeratosis congenita.Blood 120,2990–3000(2012).

[0304] 21.Bar,C.et al.Telomerase gene therapy rescues telomere length,bonemarrow aplasia and survival in micewith aplastic anemia.Blood 127,1770–1779(2016).

[0305] 22.Povedano,J.M.,Martinez,P.,Flores,J.M.,Mulero,F.&Blasco,M.A.Micewith pulmonary fibrosisdriven by telomere dysfunction.Cell Rep.12,86–299(2015).

[0306] 23.Povedano,J.M.et al.Therapeutic effects of telomerase in mice withpulmonary fibrosis induced bydamage to the lungs and short telomeres.eLife 7,e31299(2018).

[0307] 24.Blasco,M.A.et al.Telomere shortening and tumor formation by mousecells lacking telomerase RNA.Cell 91,25–34(1997).

[0308] 25.Lee,H.W.et al.Essential role of mouse telomerase in highlyproliferative organs.Nature 392,569–574(1998).

[0309] 26.Herrera,E.et al.Disease states associated with telomerasedeficiency appear earlier in mice with shorttelomeres.EMBO J.18,2950–2960(1999).

[0310] 27.Bajwa,A.et al.Sphingosine kinase 2 deficiency attenuates kidneyfibrosis via IFN-γ.J.Am.Soc.Nephrol.28,1145–1161(2017).

[0311] 28.Yang,B.et al.PHF14:an innate inhibitor against the progression ofrenal fibrosis following folic acid-induced kidney injury.Sci.Rep.7,39888(2017).

[0312] 29.Long,D.A.,Woolf,A.S.,Suda,T.&Yuan,H.T.Increased renalangiopoietin-1 expression in folic acid-induced nephrotoxicity inmice.J.Am.Soc.Nephrol.12,2721–2731(2001).

[0313] 30.Damera,S.et al.Serum alkaline phosphatase levels associate withelevated serum C-reactive protein inchronic kidney disease.Kidney Int.79,228–233(2011).

[0314] 31.Leibovitch,I.,Ben-Chaim,J.,Ramon,J.&Goldwasser,B.Increased serumalkaline phosphatase activity:a possible indicator of renaldamage.J.Clin.Lab.Anal.5,406–409(1991).

[0315] 32.Collen,M.J.,Ansher,A.F.,Chapman,A.B.,Mackow,R.C.&Lewis,J.H.Serumamylase in patientswith renal insufficiency and renalfailure.Am.J.Gastroenterol.85,1377–1380(1990).

[0316] 33.Moyses-Neto,M.et al.Acute renal failure andhypercalcemia.Ren.Fail.28,153–159(2006).

[0317] 34.Barreto,F.C.,Barreto,D.V.,Massy,Z.A.&Drueke,T.B.Strategies forphosphate control in patientswith CKD.Kidney Int.Rep.4,1043–1056(2019).

[0318] 35.Cole,N.I.et al.Serum sodium concentration and the progression ofestablished chronic kidney disease.J.Nephrol.32,259–264(2019).

[0319] 36.Korgaonkar,S.et al.Serum potassium and outcomes in CKD:insightsfrom the RRI-CKD cohort study.Clin.J.Am.Soc.Nephrol.5,762–769(2010).

[0320] 37.Yang,H.-C.,Zuo,Y.&Fogo,A.B.Models of chronic kidney disease.DrugDiscov.Today Dis.Models7,13–19(2010).

[0321] 38.Kalluri,R.&Neilson,E.G.Epithelial–mesenchymal transition and itsimplications for fibrosis.J.Clin.Invest.112,1776–1784(2003).

[0322] 39.Blasco,M.A.Telomere length,stem cells and aging.Nat.Chem.Biol.3,640–649(2007).

[0323] 40.d’Adda di Fagagna,F.et al.ADNA damage checkpoint response intelomere-initiated senescence.Nature426,194–198(2003).

[0324] 41.Gonzalez-Suarez,E.,Samper,E.,Flores,J.M.&Blasco,M.A.Telomerase-deficient mice with shorttelomeres are resistant to skintumorigenesis.Nat.Genet.26,114–117(2000).

[0325] 42.Han,W.K.,Bailly,V.,Abichandani,R.,Thadhani,R.&Bonventre,J.V.Kidneyinjury molecule-1(KIM-1):a novel biomarker for human renal proximal tubuleinjury.Kidney Int.62,237–244(2002).

[0326] 43.Humphreys,B.D.et al.Chronic epithelial kidney injury molecule-1expression causes murine kidneyfibrosis.J.Clin.Invest.123,4023–4035(2013).

[0327] 44.Nickolas,T.L.et al.Sensitivity and specificity of a singleemergency department measurement of urinaryneutrophil gelatinase-associatedlipocalin for diagnosing acute kidney injury.Ann.Intern.Med.148,810–819(2008).

[0328] 45.Stemmler,M.P.,Eccles,R.L.,Brabletz,S.&Brabletz,T.Non-redundantfunctions of EMT transcriptionfactors.Nat.Cell Biol.21,102–112(2019).

[0329] 46.Lovisa,S.et al.Epithelial-to-mesenchymal transition induces cellcycle arrest and parenchymal damagein renal fibrosis.Nat.Med.21,998–1009(2015).

[0330] 47.Schietke,R.et al.The lysyl oxidases LOX and LOXL2 are necessaryand sufficient to repress E-cadherinin hypoxia:insights into cellulartransformation processes mediated by HIF-1.J.Biol.Chem.285,6658–6669(2010).

[0331] 48.Reginensi,A.et al.SOX9 controls epithelial branching by activatingRET effector genes during kidneydevelopment.Hum.Mol.Genet.20,1143–1153(2011).

[0332] 49. N.O.et al.Progressive recruitment of mesenchymalprogenitors reveals a time-dependentprocess of cell fate acquisition in mouseand human nephrogenesis.Dev.Cell 45,651–660(2018).

[0333] 50.Angelotti,M.L.et al.Characterization of renal progenitorscommitted toward tubular lineage and theirregenerative potential in renaltubular injury.Stem Cells 30,1714–1725(2012).

[0334] 51.Davies,J.A.et al.Development of an siRNA-based method forrepressing specific genes in renal organculture and its use to show that theWt1 tumour suppressor is required for nephron differentiation.Hum.Mol.Genet.13,235–246(2004).

[0335] 52.Rothenpieler,U.W.&Dressler,G.R.Pax-2 is required for mesenchyme-to-epithelium conversion duringkidney development.Development 119,711–720(1993).

[0336] 53.Huang,B.et al.Wt1 and Pax2 re-expression is required forepithelial–mesenchymal transition in 5 / 6nephrectomized rats and culturedkidney tubular epithelial cells.Cells Tissues Organs 195,296–312(2012).

[0337] 54.Ma,Y.et al.Cloning and characterization of two promoters for thehuman HSAL2 gene and theirtranscriptional repression by the Wilms’tumorsuppressor gene product.J.Biol.Chem.276,48223–48230(2001).

[0338] 55.Xu,Y.&Sun,Z.Molecular basis of Klotho:from gene to function inaging.Endocr.Rev.36,174–193(2015).

[0339] 56.Vera,E.,Bernardes de Jesus,B.,Foronda,M.,Flores,J.M.&Blasco,M.A.Telomerase reversetranscriptase synergizes with calorie restriction toincrease health span and extend mouse longevity.PLoS ONE 8,e53760(2013).

[0340] 57.Bielesz,B.et al.Epithelial Notch signaling regulates interstitialfibrosis development in the kidneys ofmice and humans.J.Clin.Invest.120,4040–4054(2010).

[0341] 58.Edeling,M.,Ragi,G.,Huang,S., H.&Susztak,K.Developmentalsignalling pathways inrenal fibrosis:the roles of Notch,Wnt andHedgehog.Nat.Rev.Nephrol.12,426–439(2016).

[0342] 59.Huang,S.et al.Jagged1 / Notch2 controls kidney fibrosis via Tfam-mediated metabolic reprogramming.PLoS Biol.16,e2005233(2018).

[0343] 60.Bejarano,L.et al.Safety of whole-body abrogation of the TRF1shelterin protein in wild-type and cancer-prone mouse models.iScience 19,572–585(2019).

[0344] 61.Greider,C.W.&Blackburn,E.H.The telomere terminal transferase ofetrahymena is a ribonucleoproteinenzyme with two kinds of primerspecificity.Cell 51,887–898(1987).

[0345] 62.Fazilaty,H.et al.A gene regulatory network to control EMT programsin development and disease.Nat.Commun.10,5115(2019).

[0346] 63.Liu,Y.et al.The telomerase reverse transcriptase is limiting andnecessary for telomerase function in vivo.Curr.Biol.10,1459–1462(2000).

[0347] 64.Martínez,P.et al.Increased telomere fragility and fusionsresulting from TRF1 deficiency lead todegenerative pathologies and increasedcancer in mice.Genes Dev.23,2060–2075(2009).

[0348] 65.Ruzankina,Y.et al.Deletion of the developmentally essential geneATR in adult mice leads to age-relatedphenotypes and stem cell loss.Cell StemCell 1,113–126(2007).

[0349] 66.Terryn,S.et al.Aprimary culture of mouse proximal tubular cells,established on collagen-coatedmembranes.Am.J.Physiol.Renal Physiol.293,F476–F485(2007).

[0350] 67. O.,Rubio-Camarillo,M.,Fdez-Riverola,F.,Pisano,D.G.& D.Nextpresso:next-generation sequencing expression analysispipeline.Curr.Bioinform.13,583–591(2017).

[0351] 68.Trapnell,C.et al.Differential gene and transcript expressionanalysis of RNA-seq experiments withTopHat and Cufflinks.Nat.Protoc.7,562–578(2012).

[0352] 69.Langmead,B.,Trapnell,C.,Pop,M.&Salzberg,S.L.Ultrafast and memory-efficient alignment of shortDNAsequences to the human genome.Genome Biol.10,R25(2009).

[0353] 70.Li,H.et al.The Sequence Alignment / Map format andSAMtools.Bioinformatics 25,2078–2079(2009).

[0354] 71.Anders,S.,Pyl,P.T.&Huber,W.HTSeq—a Python framework to work withhigh-throughput sequencingdata.Bioinformatics 31,166–169(2015).

[0355] 72.Subramanian,A.et al.Gene-set enrichment analysis:a knowledge-basedapproach for interpretinggenome-wide expression profiles.Proc.NatlAcad.Sci.USA 102,15545–15550(2005).

[0356] 73.Harley et al.,1990.Nature 345,458-460;Blasco,2007.Nat Chem Biol.3,640-649

[0357] 74.Flores et al,2008.Genes and Dev 22,654-667

[0358] 75.Foust et al Nature biotechnology 2009;

[0359] 76.Heilbronn&Weger(2010)Handb Exp Pharmacol.197:143-70

[0360] 77. Bernardes de Jesus et al., 2012 EMBO Mol Med. 2012 Aug; 4(8): 691-704. doi: 10.1002 / emmm.201200245.

[0361] 78. Duque et al Molecular therapy 2009. Sequence Listing <110> Carlos III Oncology Research Center National Public Sector Foundation (FSP CNIO) <120> Telomerase reverse transcriptase therapy for renal fibrosis and non-human animals thereof <130> 906 411 <160> 49 <170> BiSSAP 1.3.6 <210> 1 <211> 4018 <212> DNA <213> Homo sapiens <400> 1 caggcagcgc tgcgtcctgc tgcgcacgtg ggaagccctg gccccggcca cccccgcgat 60 gccgcgcgct ccccgctgcc gagccgtgcg ctccctgctg cgcagccact accgcgaggt 120 gctgccgctg gccacgttcg tgcggcgcct ggggccccag ggctggcggc tggtgcagcg 180 cggggacccg gcggctttcc gcgcgctggt ggcccagtgc ctggtgtgcg tgccctggga 240 cgcacggccg ccccccgccg ccccctcctt ccgccaggtg tcctgcctga aggagctggt 300 ggcccgagtg ctgcagaggc tgtgcgagcg cggcgcgaag aacgtgctgg ccttcggctt 360 cgcgctgctg gacggggccc gcgggggccc ccccgaggcc ttcaccacca gcgtgcgcag 420 ctacctgccc aacacggtga ccgacgcact gcgggggagc ggggcgtggg ggctgctgct 480 gcgccgcgtg ggcgacgacg tgctggttca cctgctggca cgctgcgcgc tctttgtgct 540 ggtggctccc agctgcgcct accaggtgtg cgggccgccg ctgtaccagc tcggcgctgc 600 cactcaggcc cggcccccgc cacacgctag tggaccccga aggcgtctgg gatgcgaacg 660 ggcctggaac catagcgtca gggaggccgg ggtccccctg ggcctgccag ccccgggtgc 720 gaggaggcgc gggggcagtg ccagccgaag tctgccgttg cccaagaggc ccaggcgtgg 780 cgctgcccct gagccggagc ggacgcccgt tgggcagggg tcctgggccc acccgggcag 840 gacgcgtgga ccgagtgacc gtggtttctg tgtggtgtca cctgccagac ccgccgaaga 900 agccacctct ttggagggtg cgctctctgg cacgcgccac tcccacccat ccgtgggccg 960 1020. cgcctggg acacgccttg tcccccggtg tacgccgaga ccaagcactt cctctactcc tcaggcgaca aggagcagct gcggccctcc ttcctactca gctctctgag gcccagcctg actggcgctc ggaggctcgt 1140 ggagaccatc tttctgggtt ccaggccctg gatgccaggg actccccgca ggttgccccg cctgccccag cgctactggc aaatgcggcc cctgtttctg gagctgcttg ggaaccacgc gcagtgcccc tacggggtgc tcctcaagac gcactgcccg ctgcgagctg cggtcacccc 1320 agcagccggt gtctgtgccc gggagagcc ccagggctct gtggcggccc ccgagga 1380 ggacacagac ccccgtcgcc tggtgcagct gctccgccag cacagcagcc cctggcaggt gtacggcttc gtgcggggcct gcctgcgccg gctggtgccc ccaggcctct ggggctccag gcacaacgaa cgccgcttcc tcaggaacac caagaagttc atctccctgg ggaagcatgc caagctctcg ctgcaggagc tgacgtggaa gatgagcgtg cgggactgcg cttggctgcg caggagccca ggggttggct gtgttccggc cgcagagcac cgtctgcgtg aggagatcct 1680 ggccaagttc ctgcactggc tgatgagtgt gtacgtcgtc gagctgctca ggtctttctt 1740 ttatgtcacg gagaccacgt ttcaaaagaa caggctcttt ttctaccgga agagtgtctg 1800 gagcaagttg caaagcattg gaatcagaca gcacttgaag agggtgcagc tgcgggagct 1860 gtcggaagca gaggtcaggc agcatcggga agccaggccc gccctgctga cgtccagact 1920 ccgcttcatc cccaagcctg acgggctgcg gccgattgtg aacatggact acgtcgtggg 1980 agccagaacg ttccgcagag aaaagagggc cgagcgtctc acctcgaggg tgaaggcact 2040 gttcagcgtg ctcaactacg agcgggcgcg gcgccccggc ctcctgggcg cctctgtgct 2100 gggcctggac gatatccaca gggcctggcg caccttcgtg ctgcgtgtgc gggcccagga 2160 cccgccgcct gagctgtact ttgtcaaggt ggatgtgacg ggcgcgtacg acaccatccc 2220 ccaggacagg ctcacggagg tcatcgccag catcatcaaa ccccagaaca cgtactgcgt 2280 gcgtcggtat gccgtggtcc agaaggccgc ccatgggcac gtccgcaagg ccttcaagag 2340 ccacgtctct accttgacag acctccagcc gtacatgcga cagttcgtgg ctcacctgca 2400 ggagaccagc ccgctgaggg atgccgtcgt catcgagcag agctcctccc tgaatgaggc 2460 cagcagtggc ctcttcgacg tcttcctacg cttcatgtgc caccacgccg tgcgcatcag 2520 gggcaagtcc tacgtccagt gccaggggat cccgcagggc tccatcctct ccacgctgct 2580 ctgcagcctg tgctacggcg acatggagaa caagctgttt gcggggattc ggcgggacgg 2640 gctgctcctg cgtttggtgg atgatttctt gttggtgaca cctcacctca cccacgcgaa 2700 aaccttcctc aggaccctgg tccgaggtgt ccctgagtat ggctgcgtgg tgaacttgcg 2760 gaagacagtg gtgaacttcc ctgtagaaga cgaggccctg ggtggcacgg cttttgttca 2820 gatgccggcc cacggcctat tcccctggtg cggcctgctg ctggataccc ggaccctgga 2880 ggtgcagagc gactactcca gctatgcccg gacctccatc agagccagtc tcaccttcaa 2940 ccgcggcttc aaggctggga ggaacatgcg tcgcaaactc tttggggtct tgcggctgaa 3000 gtgtcacagc ctgtttctgg atttgcaggt gaacagcctc cagacggtgt gcaccaacat 3060 ctacaagatc ctcctgctgc aggcgtacag gtttcacgca tgtgtgctgc agctcccatt 3120 tcatcagcaa gtttggaaga accccacatt tttcctgcgc gtcatctctg acacggcctc 3180 cctctgctac tccatcctga aagccaagaa cgcagggatg tcgctggggg ccaagggcgc 3240 cgccggccct ctgccctccg aggccgtgca gtggctgtgc caccaagcat tcctgctcaa 3300 gctgactcga caccgtgtca cctacgtgcc actcctgggg tcactcagga cagcccagac 3360 gcagctgagt cggaagctcc cggggacgac gctgactgcc ctggaggccg cagccaaccc 3420 ggcactgccc tcagacttca agaccatcct ggactgatgg ccacccgccc acagccaggc 3480 cgagagcaga caccagcagc cctgtcacgc cgggctctac gtcccaggga gggaggggcg 3540 gcccacaccc aggcccgcac cgctgggagt ctgaggcctg agtgagtgtt tggccgaggc 3600 ctgcatgtcc ggctgaaggc tgagtgtccg gctgaggcct gagcgagtgt ccagccaagg 3660 gctgagtgtc cagcacacct gccgtcttca cttccccaca ggctggcgct cggctccacc 3720 ccagggccag cttttcctca ccaggagccc ggcttccact ccccacatag gaatagtcca 3780 tccccagatt cgccattgtt cacccctcgc cctgccctcc tttgccttcc acccccacca 3840 tccaggtgga gaccctgaga aggaccctgg gagctctggg aatttggagt gaccaaaggt 3900 gtgccctgta cacaggcgag gaccctgcac ctggatgggg gtccctgtgg gtcaaattgg 3960 ggggaggtgc tgtgggagta aaatactgaa tatatgagtt tttcagtttt gaaaaaaa 4018 <210> 2 <211> 1132 <212> PRT <213> Homo sapiens <400> 2 Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser 1 5 10 15 His Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly 20 25 30 Pro Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg 35 40 45 Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro 50 55 60 Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu 65 70 75 80 Val Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn Val 85 90 95 Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro 100 105 110 Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr 115 120 125 Asp Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val 130 135 140 Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe Val 145 150 155 160 Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr 165 170 175 Gln Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser Gly 180 185 190 Pro Arg Arg Arg Leu Gly Cys Glu Arg Ala Trp Asn His Ser Val Arg 195 200 205 Glu Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg 210 215 220 Gly Gly Ser Ala Ser Arg Ser Leu Pro Leu Pro Lys Arg Pro Arg Arg 225 230 235 240 Gly Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp 245 250 255 Ala His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val 260 265 270 Val Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala 275 280 285 Leu Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His 290 295 300 Ala Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr Pro 305 310 315 320 Cys Pro Pro Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser Gly 325 330 335 Asp Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg Pro 340 345 350 Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser 355 360 365 Arg Pro Trp Met Pro Gly Thr Pro Arg Arg Leu Pro Arg Leu Pro Gln 370 375 380 Arg Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His 385 390 395 400 Ala Gln Cys Pro Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg 405 410 415 Ala Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln 420 425 430 Gly Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu 435 440 445 Val Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe 450 455 460 Val Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser 465 470 475 480 Arg His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser 485 490 495 Leu Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met 500 505 510 Ser Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys 515 520 525 Val Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe 530 535 540 Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe 545 550 555 560 Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr 565 570 575 Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His 580 585 590 Leu Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln 595 600 605 His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile 610 615 620 Pro Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val 625 630 635 640 Gly Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser 645 650 655 Arg Val Lys Ala Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg 660 665 670 Pro Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His Arg 675 680 685 Ala Trp Arg Thr Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro Pro 690 695 700 Glu Leu Tyr Phe Val Lys Val Asp Val Thr Gly Ala Tyr Asp Thr Ile 705 710 715 720 Pro Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro Gln 725 730 735 Asn Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Gln Lys Ala Ala His 740 745 750 Gly His Val Arg Lys Ala Phe Lys Ser His Val Ser Thr Leu Thr Asp 755 760 765 Leu Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr Ser 770 775 780 Pro Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn Glu 785 790 795 800 Ala Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Met Cys His His 805 810 815 Ala Val Arg Ile Arg Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile Pro 820 825 830 Gln Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly Asp 835 840 845 Met Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu Leu 850 855 860 Arg Leu Val Asp Asp Phe Leu Leu Val Thr Pro His Leu Thr His Ala 865 870 875 880 Lys Thr Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly Cys 885 890 895 Val Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp Glu 900 905 910 Ala Leu Gly Gly Thr Ala Phe Val Gln Met Pro Ala His Gly Leu Phe 915 920 925 Pro Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln Ser 930 935 940 Asp Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr Phe 945 950 955 960 Asn Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe Gly 965 970 975 Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Asp Leu Gln Val Asn 980 985 990 Ser Leu Gln Thr Val Cys Thr Asn Ile Tyr Lys Ile Leu Leu Leu Gln 995 1000 1005 Ala Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe His Gln Gln 1010 1015 1020 Val Trp Lys Asn Pro Thr Phe Phe Leu Arg Val Ile Ser Asp Thr Ala 1025 1030 1035 1040 Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly Met Ser Leu 1045 1050 1055 Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu Ala Val Gln Trp 1060 1065 1070 Leu Cys His Gln Ala Phe Leu Leu Lys Leu Thr Arg His Arg Val Thr 1075 1080 1085 Tyr Val Pro Leu Gly Ser Leu Arg Thr Ala Gln Thr Gln Leu Ser 1090 1095 1100 Arg Lys Leu Pro Gly Thr Thr Leu Thr Ala Leu Glu Ala Ala Ala Ala Asn 1105 1110 1115 1120 Pro Ala Leu Pro Ser Asp Phe Lys Thr Ile Leu Asp 1125 1130 <210> 3 <211> 3982 <212> DNA <213> Homo sapiens <400> 3 caggcagcgc tgcgtcctgc tgcgcacgtg ggaagccctg gccccggcca cccccgcgat 60 gccgcgcgct cccgctgcc gagccgtgcg ctcctgctg cgcagccact accgcgaggt 120 gctgccgctg gccacgttcg tgcggcgcct ggggccccag ggctgcggc tggtgcagcg 180 cggggacccg gcggctttcc gcgcgctggt ggcccagtgc ctggtgtgcg tgccctggga 240 cgcacggccg ccccccgccg ccccctcctt ccgccaggtg tcctgcctga aggagctggt 300 ggcccgagtg ctgcagaggc tgtgcgagcg cggcgcgaag aacgtgctgg ccttcggctt 360 cgcgctgctg gacggggccc gcgggggccc ccccgaggcc ttcaccacca gcgtgcgcag 420 ctacctgccc aacacggtga ccgacgcact gcgggggagc ggggcgtggg ggctgctgct 480 gcgccgcgtg ggcgacgacg tgctggttca cctgctggca cgctgcgcgc tctttgtgct 540 ggtggctccc agctgcgcct accaggtgtg cgggccgccg ctgtaccagc tcggcgctgc 600 cactcaggcc cggcccccgc cacacgctag tggaccccga aggcgtctgg gatgcgaacg 660 ggcctggaac catagcgtca gggaggccgg ggtccccctg ggcctgccag ccccgggtgc 720 gaggaggcgc gggggcagtg ccagccgaag tctgccgttg cccaagaggc ccaggcgtgg 780 cgctgcccct gagccggagc ggacgcccgt tgggcagggg tcctgggccc acccgggcag 840 gacgcgtgga ccgagtgacc gtggtttctg tgtggtgtca cctgccagac ccgccgaaga 900 agccacctct ttggagggtg cgctctctgg cacgcgccac tcccacccat ccgtgggccg 960 ccagcaccac gcgggccccc catccacatc gcggccacca cgtccctggg acacgccttg 1020 tcccccggtg tacgccgaga ccaagcactt cctctactcc tcaggcgaca aggagcagct 1080 gcggccctcc ttcctactca gctctctgag gcccagcctg actggcgctc ggaggctcgt 1140 ggagaccatc tttctgggtt ccaggccctg gatgccaggg actccccgca ggttgccccg 1200 cctgccccag cgctactggc aaatgcggcc cctgtttctg gagctgcttg ggaaccacgc 1260 gcagtgcccc tacggggtgc tcctcaagac gcactgcccg ctgcgagctg cggtcacccc 1320 agcagccggt gtctgtgccc gggagaagcc ccagggctct gtggcggccc ccgaggagga 1380 ggacacagac ccccgtcgcc tggtgcagct gctccgccag cacagcagcc cctggcaggt 1440 gtacggcttc gtgcgggcct gcctgcgccg gctggtgccc ccaggcctct ggggctccag 1500 gcacaacgaa cgccgcttcc tcaggaacac caagaagttc atctccctgg ggaagcatgc 1560 caagctctcg ctgcaggagc tgacgtggaa gatgagcgtg cgggactgcg cttggctgcg 1620 caggagccca ggggttggct gtgttccggc cgcagagcac cgtctgcgtg aggagatcct 1680 ggccaagttc ctgcactggc tgatgagtgt gtacgtcgtc gagctgctca ggtctttctt 1740 ttatgtcacg gagaccacgt ttcaaaagaa caggctcttt ttctaccgga agagtgtctg 1800 gagcaagttg caaagcattg gaatcagaca gcacttgaag agggtgcagc tgcgggagct 1860 gtcggaagca gaggtcaggc agcatcggga agccaggccc gccctgctga cgtccagact 1920 ccgcttcatc cccaagcctg acgggctgcg gccgattgtg aacatggact acgtcgtggg 1980 agccagaacg ttccgcagag aaaagagggc cgagcgtctc acctcgaggg tgaaggcact 2040 gttcagcgtg ctcaactacg agcgggcgcg gcgccccggc ctcctgggcg cctctgtgct 2100 gggcctggac gatatccaca gggcctggcg caccttcgtg ctgcgtgtgc gggcccagga 2160 cccgccgcct gagctgtact ttgtcaagga caggctcacg gaggtcatcg ccagcatcat 2220 caaaccccag aacacgtact gcgtgcgtcg gtatgccgtg gtccagaagg ccgcccatgg 2280 gcacgtccgc aaggccttca agagccacgt ctctaccttg acagacctcc agccgtacat 2340 gcgacagttc gtggctcacc tgcaggagac cagcccgctg agggatgccg tcgtcatcga 2400 gcagagctcc tccctgaatg aggccagcag tggcctcttc gacgtcttcc tacgcttcat 2460 gtgccaccac gccgtgcgca tcaggggcaa gtcctacgtc cagtgccagg ggatcccgca 2520 gggctccatc ctctccacgc tgctctgcag cctgtgctac ggcgacatgg agaacaagct 2580 gtttgcgggg attcggcggg acgggctgct cctgcgtttg gtggatgatt tcttgttggt 2640 gacacctcac ctcacccacg cgaaaacctt cctcaggacc ctggtccgag gtgtccctga 2700 gtatggctgc gtggtgaact tgcggaagac agtggtgaac ttccctgtag aagacgaggc 2760 cctgggtggc acggcttttg ttcagatgcc ggcccacggc ctattcccct ggtgcggcct 2820 gctgctggat acccggaccc tggaggtgca gagcgactac tccagctatg cccggacctc 2880 catcagagcc agtctcacct tcaaccgcgg cttcaaggct gggaggaaca tgcgtcgcaa 2940 actctttggg gtcttgcggc tgaagtgtca cagcctgttt ctggatttgc aggtgaacag 3000 cctccagacg gtgtgcacca acatctacaa gatcctcctg ctgcaggcgt acaggtttca 3060 cgcatgtgtg ctgcagctcc catttcatca gcaagtttgg aagaacccca catttttcct 3120 gcgcgtcatc tctgacacgg cctccctctg ctactccatc ctgaaagcca agaacgcagg 3180 gatgtcgctg ggggccaagg gcgccgccgg ccctctgccc tccgaggccg tgcagtggct 3240 gtgccaccaa gcattcctgc tcaagctgac tcgacaccgt gtcacctacg tgccactcct 3300 ggggtcactc aggacagccc agacgcagct gagtcggaag ctcccgggga cgacgctgac 3360 tgccctggag gccgcagcca acccggcact gccctcagac ttcaagacca tcctggactg 3420 atggccaccc gcccacagcc aggccgagag cagacaccag cagccctgtc acgccgggct 3480 ctacgtccca gggagggagg ggcggcccac acccaggccc gcaccgctgg gagtctgagg 3540 cctgagtgag tgtttggccg aggcctgcat gtccggctga aggctgagtg tccggctgag 3600 gcctgagcga gtgtccagcc aagggctgag tgtccagcac acctgccgtc ttcacttccc 3660 cacaggctgg cgctcggctc caccccaggg ccagcttttc ctcaccagga gcccggcttc 3720 cactccccac ataggaatag tccatcccca gattcgccat tgttcacccc tcgccctgcc 3780 ctcctttgcc ttccaccccc accatccagg tggagaccct gagaaggacc ctgggagctc 3840 tgggaatttg gagtgaccaa aggtgtgccc tgtacacagg cgaggaccct gcacctggat 3900 gggggtccct gtgggtcaaa ttggggggag gtgctgtggg agtaaaatac tgaatatatg 3960 agtttttcag ttttgaaaaa aa 3982 <210> 4 <211> 1120 <212> PRT <213> Homo sapiens <400> 4 Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser 1 5 10 15 His Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly 20 25 30 Pro Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg 35 40 45 Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro 50 55 60 Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu 65 70 75 80 Val Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn Val 85 90 95 Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro 100 105 110 Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr 115 120 125 Asp Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val 130 135 140 Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe Val 145 150 155 160 Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr 165 170 175 Gln Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser Gly 180 185 190 Pro Arg Arg Arg Leu Gly Cys Glu Arg Ala Trp Asn His Ser Val Arg 195 200 205 Glu Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg 210 215 220 Gly Gly Ser Ala Ser Arg Ser Leu Pro Leu Pro Lys Arg Pro Arg Arg 225 230 235 240 Gly Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp 245 250 255 Ala His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val 260 265 270 Val Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala 275 280 285 Leu Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His 290 295 300 Ala Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr Pro 305 310 315 320 Cys Pro Pro Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser Gly 325 330 335 Asp Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg Pro 340 345 350 Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser 355 360 365 Arg Pro Trp Met Pro Gly Thr Pro Arg Arg Leu Pro Arg Leu Pro Gln 370 375 380 Arg Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His 385 390 395 400 Ala Gln Cys Pro Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg 405 410 415 Ala Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln 420 425 430 Gly Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu 435 440 445 Val Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe 450 455 460 Val Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser 465 470 475 480 Arg His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser 485 490 495 Leu Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met 500 505 510 Ser Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys 515 520 525 Val Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe 530 535 540 Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe 545 550 555 560 Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr 565 570 575 Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His 580 585 590 Leu Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln 595 600 605 His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile 610 615 620 Pro Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val 625 630 635 640 Gly Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser 645 650 655 Arg Val Lys Ala Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg 660 665 670 Pro Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His Arg 675 680 685 Ala Trp Arg Thr Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro Pro 690 695 700 Glu Leu Tyr Phe Val Lys Asp Arg Leu Thr Glu Val Ile Ala Ser Ile 705 710 715 720 Ile Lys Pro Gln Asn Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Gln 725 730 735 Lys Ala Ala His Gly His Val Arg Lys Ala Phe Lys Ser His Val Ser 740 745 750 Thr Leu Thr Asp Leu Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu 755 760 765 Gln Glu Thr Ser Pro Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser 770 775 780 Ser Leu Asn Glu Ala Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe 785 790 795 800 Met Cys His His Ala Val Arg Ile Arg Gly Lys Ser Tyr Val Gln Cys 805 810 815 Gln Gly Ile Pro Gln Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu 820 825 830 Cys Tyr Gly Asp Met Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp 835 840 845 Gly Leu Leu Leu Arg Leu Val Asp Asp Phe Leu Leu Val Thr Pro His 850 855 860 Leu Thr His Ala Lys Thr Phe Leu Arg Thr Leu Val Arg Gly Val Pro 865 870 875 880 Glu Tyr Gly Cys Val Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro 885 890 895 Val Glu Asp Glu Ala Leu Gly Gly Thr Ala Phe Val Gln Met Pro Ala 900 905 910 His Gly Leu Phe Pro Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu 915 920 925 Glu Val Gln Ser Asp Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala 930 935 940 Ser Leu Thr Phe Asn Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg 945 950 955 960 Lys Leu Phe Gly Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Asp 965 970 975 Leu Gln Val Asn Ser Leu Gln Thr Val Cys Thr Asn Ile Tyr Lys Ile 980 985 990 Leu Leu Leu Gln Ala Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro 995 1000 1005 Phe His Gln Gln Val Trp Lys Asn Pro Thr Phe Phe Leu Arg Val Ile 1010 1015 1020 Ser Asp Thr Ala Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala 1025 1030 1035 1040 Gly Met Ser Leu Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu 1045 1050 1055 Ala Val Gln Trp Leu Cys His Gln Ala Phe Leu Leu Lys Leu Thr Arg 1060 1065 1070 His Arg Val Thr Tyr Val Pro Leu Leu Gly Ser Leu Arg Thr Ala Gln 1075 1080 1085 Thr Gln Leu Ser Arg Lys Leu Pro Gly Thr Thr Leu Thr Ala Leu Glu 1090 1095 1100 Ala Ala Ala Asn Pro Ala Leu Pro Ser Asp Phe Lys Thr Ile Leu Asp 1105 1110 1115 1120 <210> 5 <211> 3426 <212> DNA <213> Mus musculus <400> 5 gtgggaggcc catcccggcc ttgagcacaa tgacccgcgc tcctcgttgc cccgcggtgc 60 gctctctgct gcgcagccga taccgggagg tgtggccgct ggcaaccttt gtgcggcgcc 120 tggggcccga gggcaggcgg cttgtgcaac ccggggaccc gaagatctac cgcactttgg 180 ttgcccaatg cctagtgtgc atgcactggg gctcacagcc tccacctgcc gacctttcct 240 tccaccaggt gtcatccctg aaagagctgg tggccagggt tgtgcagaga ctctgcgagc 300 gcaacgagag aaacgtgctg gcttttggct ttgagctgct taacgaggcc agaggcgggc 360 ctcccatggc cttcactagt agcgtgcgta gctacttgcc caacactgtt attgagaccc 420 tgcgtgtcag tggtgcatgg atgctactgt tgagccgagt gggcgacgac ctgctggtct 480 acctgctggc acactgtgct ctttatcttc tggtgccccc cagctgtgcc taccaggtgt 540 gtgggtctcc cctgtaccaa atttgtgcca ccacggatat ctggccctct gtgtccgcta 600 gttacaggcc cacccgaccc gtgggcagga atttcactaa ccttaggttc ttaacaagaga 660 720 agaggcatct gagtctcacc agtacaagtg tgccttcagc taagaaggcc agatgctatc 780 ctgtccccgag agtggaggag ggaccccaca ggcaggtgct accaacccca tcaggcaaat 840 catgggtgcc aagtcctgct cggtcccccg aggtgcctac tgcagaagaa gatttgtctt 900 ctaaaaa ggtgtctgac ctgagtctct ctgggtcggt gtgcttaaa caaagccca 960 gctccacatc tctgctgtca ccaccccgcc aaaatgcctt tcagctcagg ccatttattg 1020 agaccagaca tttcctttac tccaggggag atggccaaga gcgtctaaac ccctcattcc 1080 tactcagcaa cctccagcct aacttgactg gggccaggag actggtggag atcatctttc 1140 tgggctcaag gcctaggaca tcaggaccac tctgcaggac acaccgtcta tcgcgtcgat 1200 actggcagat gcggcccctg ttccaacagc tgctggtgaa ccatgcagag tgccaatatg 1260 tcagactcct caggtcacat tgcaggtttc gaacagcaaa ccaacaggtg acagatgcct 1320 tgaacaccag cccaccgcac ctcatggatt tgctccgcct gcacagcagt ccctggcagg 1380 tatatggttt tcttcgggcc tgtctctgca aggtggtgtc tgctagtctc tggggtacca 1440 ggcacaatga gcgccgcttc tttaagaact taaagaagtt catctcgttg gggaaatacg 1500 gcaagctatc actgcaggaa ctgatgtgga agatgaaagt agaggattgc cactggctcc 1560 gcagcagccc ggggaaggac cgtgtccccg ctgcagagca ccgtctgagg gagaggatcc 1620 tggctacgtt cctgttctgg ctgatggaca catacgtggt acagctgctt aggtcattct 1680 tttacatcac agagagcaca ttccagaaga acaggctctt cttctaccgt aagagtgtgt 1740 ggagcaagct gcagagcatt ggagtcaggc aacaccttga gagagtgcgg ctacgggagc 1800 tgtcacaaga ggaggtcagg catcaccagg acacctggct agccatgccc atctgcagac 1860 tgcgcttcat ccccaagccc aacggcctgc ggcccattgt gaacatgagt tatagcatgg 1920 gtaccagagc tttgggcaga aggaagcagg cccagcattt cacccagcgt ctcaagactc 1980 tcttcagcat gctcaactat gagcggacaa aacatcctca ccttatgggg tcttctgtac 2040 tgggtatgaa tgacatctac aggacctggc gggcctttgt gctgcgtgtg cgtgctctgg 2100 accagacacc caggatgtac tttgttaagg cagatgtgac cggggcctat gatgccatcc 2160 cccagggtaa gctggtggag gttgttgcca atatgatcag gcactcggag agcacgtact 2220 gtatccgcca gtatgcagtg gtccggagag atagccaagg ccaagtccac aagtccttta 2280 ggagacaggt caccaccctc tctgacctcc agccatacat gggccagttc cttaagcatc 2340 tgcaggattc agatgccagt gcactgagga actccgttgt catcgagcag agcatctcta 2400 tgaatgagag cagcagcagc ctgtttgact tcttcctgca cttcctgcgt cacagtgtcg 2460 taaagattgg tgacaggtgc tatacgcagt gccagggcat cccccagggc tccagcctat 2520 ccaccctgct ctgcagtctg tgtttcggag acatggagaa caagctgttt gctgaggtgc 2580 agcgggatgg gttgctttta cgttttgttg atgactttct gttggtgacg cctcacttgg 2640 accaagcaaa aaccttcctc agcaccctgg tccatggcgt tcctgagtat gggtgcatga 2700 taaacttgca gaagacagtg gtgaacttcc ctgtggagcc tggtaccctg ggtggtgcag 2760 ctccatacca gctgcctgct cactgcctgt ttccctggtg tggcttgctg ctggacactc 2820 agactttgga ggtgttctgt gactactcag gttatgccca gacctcaatt aagacgagcc 2880 tcaccttcca gagtgtcttc aaagctggga agaccatgcg gaacaagctc ctgtcggtct 2940 tgcggttgaa gtgtcacggt ctatttctag acttgcaggt gaacagcctc cagacagtct 3000 gcatcaatat atacaagatc ttcctgcttc aggcctacag gttccatgca tgtgtgattc 3060 agcttccctt tgaccagcgt gttaggaaga acctcacatt ctttctgggc atcatctcca 3120 gccaagcatc ctgctgctat gctatcctga aggtcaagaa tccaggaatg acactaaagg 3180 cctctggctc ctttcctcct gaagccgcac attggctctg ctaccaggcc ttcctgctca 3240 agctggctgc tcattctgtc atctacaaat gtctcctggg acctctgagg acagcccaaa 3300 aactgctgtg ccggaagctc ccagaggcga caatgaccat ccttaaagct gcagctgacc 3360 cagccctaag cacagacttt cagaccattt tggactaacc ctgtctcctt ccgctagatg 3420 aacatg 3426 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Acta2 F <400> 6 atcaccaact gggacgacat 20 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Acta2 R <400> 7 agtgtcggat gctcttcagg 20 <210> 8 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Vim F <400> 8 catgatgctt tgggtaaaat gg 22 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Vim R <400> 9 agtgggtgtc aaccagagga 20 <210> 10 <211> twenty two <212> DNA <213> Artificial Sequence <220> <223> Col1a1 F <400> 10 tggaatcatg gtatttggaa ca 22 <210> 11 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Col1a1 R <400> 11 tagtcgtatg ctgccttggg 20 <210> 12 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Col1a2 F <400> 12 cagggcctga tggaaacaa 19 <210> 13 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Col1a2 R <400> 13 acccctctct cctggaagc 19 <210> 14 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Col3a1 F <400> 14 ataatgggga acgtggtcct 20 <210> 15 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Col3a1 R <400> 15 tgaccatctg atccagggtt 20 <210> 16 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> Col4a1 F <400> 16 gtctggcttc tgctgctctt c 21 <210> 17 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Col4a1 R <400> 17 tcacattttc cacagccaga 20 <210> 18 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Fn1F <400> 18 cctgggagaa gtttgtgcat 20 <210> 19 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> Fn1 R <400> 19 acttggacag gtccagttgt g 21 <210> 20 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> E r1 <400> 20 gcaccatctt gctggagact 20 <210> twenty one <211> twenty two <212> DNA <213> Artificial Sequence <220> <223> R <400> twenty one ttcattgatg actttgcttt cg 22 <210> twenty two <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Tgfb1F <400> twenty two ggagagccct ggataccaac 20 <210> twenty three <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Tgfb1 R <400> twenty three atccacttcc aacccaggtc 20 <210> twenty four <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Snai1 F <400> twenty four accctgctgg tatctctccc 20 <210> 25 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Snai1 R <400> 25 tcttcacatc cgagtgggtt 20 <210> 26 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Snai2 F <400> 26 ggctgcttca aggacacatt 20 <210> 27 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Snai2 R <400> 27 gtgccctcag gtttgatctg 20 <210> 28 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Zeb1 F <400> 28 ccaagaactg ctggcaaga 19 <210> 29 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Zeb1 R <400> 29 ttcggatcat ggttttgctc 20 <210> 30 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Zeb2 F <400> 30 aaacaagcca atcccaggag 20 <210> 31 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Zeb2 R <400> 31 gagggtttgc aaggctatca 20 <210> 32 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Twist F <400> 32 cacgctgccc tcggacaa 18 <210> 33 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Twist R <400> 33 gggacgcgga catggacc 18 <210> 34 <211> twenty two <212> DNA <213> Artificial Sequence <220> <223> Kim-1 F <400> 34 ctctacctcc actcctccaa ca 22 <210> 35 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> Kim-1 R <400> 35 ctcctgagga tgtcacagtg c 21 <210> 36 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> NGAL F <400> 36 caatgtcacc tccatcctgg 20 <210> 37 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> NGAL R <400> 37 cctggagctt ggaacaaatg 20 <210> 38 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> Smad3 F <400> 38 tgaacaccaa gtgcattacc a 21 <210> 39 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Smad3 R <400> 39 aggcggcagt agataacgtg 20 <210> 40 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> Cdh1 F <400> 40 gcagaactgt ccctgtccca g 21 <210> 41 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> cdh1R <400> 41 gaacagcacg tacacagccc t 21 <210> 42 <211> twenty two <212> DNA <213> Artificial Sequence <220> <223> Loxl2 F <400> 42 cctacaaccc caaagcctat aa 22 <210> 43 <211> twenty three <212> DNA <213> Artificial Sequence <220> <223> Loxl2 R <400> 43 cgtgcagttc atagaaaact tcc 23 <210> 44 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> GAPDH F <400> 44 aggtcggtgt gaacggattt g 21 <210> 45 <211> twenty three <212> DNA <213> Artificial Sequence <220> <223> GAPDH R <400> 45 tgtagaccat gtagttgagg tca 23 <210> 46 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Trf1 F <400> 46 tggaaaatga gaaagcgagg 20 <210> 47 <211> twenty two <212> DNA <213> Artificial Sequence <220> <223> Trf1 R <400> 47 tttctgtaga ctgctggcca tt 22 <210> 48 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> mTERT F <400> 48 ggtgacagat gccttgaaca c 21 <210> 49 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> mTERT R <400> 49 gatcctctcc ctcagacggt 20

Claims

1. A nucleic acid vector comprising a coding sequence for telomerase reverse transcriptase (TERT) for use in treating renal fibrosis associated with the presence of short telomeres.

2. The nucleic acid vector for use according to claim 1, wherein TERT is encoded by a nucleic acid sequence comprising SEQ ID NO: 1 or SEQ ID NO:

3.

3. The nucleic acid vector for use according to any one of claims 1 to 2, wherein TERT comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:

4. 4 . The nucleic acid vector for use according to any one of claims 1 to 3 , wherein the nucleic acid sequence encoding TERT is operably linked to a regulatory sequence driving the expression of the coding sequence.

5. The nucleic acid vector for use according to any one of claims 1 to 4, wherein the vector is a non-integrating vector.

6. The nucleic acid carrier for use according to any one of claims 1 to 5, wherein the nucleic acid carrier is ribonucleic acid (RNA), preferably messenger RNA.

7. The nucleic acid vector for use according to any one of claims 1 to 5, wherein the vector is a non-integrating vector based on an adeno-associated virus.

8. The nucleic acid vector for use according to claim 7, wherein the vector is an adeno-associated virus-based vector derived from serotype 9 adeno-associated virus (AAV9).

9. The nucleic acid carrier for use according to claim 8, wherein the capsid of the adeno-associated virus-based carrier is made of the capsid protein of the serotype 9 adeno-associated virus (AAV9), and both ends of the nucleic acid sequence contained in the capsid are adjacent to the internal terminal repeat sequence corresponding to the serotype 2 adeno-associated virus. 10 . The nucleic acid carrier for use according to claim 9 , wherein the nucleic acid contained in the capsid includes a fragment encoding an amino acid sequence encoding TERT.

11. The nucleic acid vector for use according to any one of claims 1 to 10, wherein the vector comprises a regulatory sequence, which is a constitutive promoter, preferably a cytomegalovirus (CMV) promoter.

12. A non-human animal, characterized in that It exhibits a pathological condition of renal fibrosis, wherein said non-human animal is obtained or can be obtained when a sublethal dose of folic acid is administered to a non-human animal whose germ cells comprise genetic inactivation of both alleles of the Tert gene.

13. The non-human animal model according to claim 12, wherein the animal is a mammal, preferably a rodent.

14. The non-human animal according to any one of claims 12 or 13, wherein the sublethal dose of folic acid is a dose of up to 200 mg / kg body weight, preferably 125 mg / kg body weight.

15. The non-human animal of any one of claims 12 to 14, wherein the folic acid is administered intraperitoneally.

16. The non-human animal according to any one of claims 12 to 15, wherein folic acid is administered when the animal is between 4 and 10 weeks of age, preferably between 6 and 8 weeks of age.

17. The non-human animal of any one of claims 12 to 16, wherein folic acid is administered once.

18. The non-human animal according to any one of claims 12 to 17, wherein the germ cells comprise genetic inactivation of both alleles of the Tert gene (Tert - / - ) of non-human animals is Tert - / - The third generation (G3) of the pedigree.

Citation Information

Patent Citations

  • Telomerase reverse transcriptase-based therapies for treatment of conditions associated with myocardial infarction

    US20170191045A1

  • Telomerase reverse transcriptase-based therapies

    US20170232075A1